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Abstract 
Antiretroviral drug resistance and cytotoxic T lymphocyte (CTL) escape are considered to 
be major obstacles to effective control of human immunodeficiency virus (HIV). To 
investigate the possibility of combining drug and immune-based selective pressures to 
combat the emergence and transmission of HIV, we studied the effect of drug resistance 
mutations on CTL recognition of HIV -1 pol epitopes. Several drug resistance mutations 
sustained or even enhanced antigenicity and immunogenicity of HIV -1 epitopes. Thus, 
drug resistant HIV is susceptible to immune selective pressure which could be applied to 
combat transmission or emergence of drug resistance and enhance the immune response 
against HIV. We also observed instances of activation of CTL against a control self-
peptide derived from interferon-gamma inducible protein (IP)-30 following in vitro 
stimulation with an HIV protease (PR) peptide. We found that activation of IP-30-
specific CTL resulted from T cell cross-reactivity between the two peptides and indicates 
that HIV PR 76-84 peptide is a heteroclitic peptide variant (i.e. more immunogenic 
variant) of the IP-30 signal peptide, which may have implications for immune memory 
and autoimmunity. 
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1. Introduction and Overview 
1.1. History of HIV I AIDS 
In 1981, the first case of acquired immune deficiency syndrome (AIDS) was 
reported in a healthy homosexual male with no previous history of immune deficiency 
(1). Shortly thereafter, Barre-Sinoussi and colleagues isolated the human 
immunodeficiency virus (HIV) type 1, the aetiologic agent of AIDS, from a patient at risk 
for AIDS (2, 3). Over the past twenty years, considerable resources and research have 
been expended to address the HIV pandemic. Unfortunately, despite progress and 
advances in understanding the biology of HIV, as well as its immunopathology and the 
host immune response against it, a HIV vaccine has yet to be developed. Furthermore, 
while antiretroviral therapy (ART) has been beneficial in reducing morbidity and 
mortality, the accumulation of drug resistance mutations in treated individuals remains a 
significant obstacle to effective long-term control of HIV. Current information on HIV is 
summarized in the following sections of this introduction. 
1.2. Biology of HIV 
1.2.1. Virus Classification 
HIV is a lentivirus of the retroviridae family of viruses. These viruses possess the 
enzyme reverse transcripase (RT), which is responsible for reverse transcribing the viral 
ribonucleic acid (RNA) genome into deoxyribonucleic acid (DNA) for integration into 
the host cell genome. Its classification as a member of the lenti virus genus reflects the 
long incubation period between primary HIV infection and development of AIDS. 
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1.2.2. Virus Structure 
The mature HIV virion (Figure 1), approximately 80-100 nm in diameter, is 
enveloped by a lipid bilayer derived from the host cell membrane. Anchored to this 
membrane are envelope glycoproteins, i.e., gp120, a surface molecule (SU), and gp41, a 
transmembrane protein (TM), which are involved in virus attachment and entry (4). 
Since mv acquires its membrane by budding from infected cells, several host cell-
derived proteins such as major histocompatibility complex (MHC) class I and II antigens 
are also found on the surface of the mature virion. The nucleocapsid core contains two 
copies of the plus sense single stranded (ss) RNA genome stabilized by the nucleocapsid 
protein p7 (NC). The core also encapsulates the viral enzymes reverse transriptase (RT), 
integrase (IN) and protease (PR). 
su 
TM 
CA t) 
MA 0 RNA 
NC 8 
p6 0 
RT 
PR 0 
HLA class I 
Vpr d IN Lipid 
Figure 1. Schematic representation of mature IDV -1 virion [adapted from Coffin, J. 
M., Cold Spring Harbor Laboratory. Press. 2002. Retroviruses. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY] 
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1.2.3. Viral Genome 
The genomic organization of HIV is depicted in Figure 2. The HIV genome is 
approximately 10,000 bases. All simple retroviruses contain three common essential 
genes: gag, pol, and env, which encode core proteins, viral enzymes and structural 
proteins, respectively. Complex retroviruses, such as HIV, encode additional regulatory 
proteins. HIV encodes six accessory proteins: i) tat promotes processivity of 
transcription by RNA polymerase complex IT (5, 6); ii) rev is responsible for nuclear 
export of unspliced viral RNA transcripts (7); iii) nef selectively downregulates MHC 
class I antigens to prevent cytotoxic T lymphocyte (CTL) and natural killer (NK) cell-
mediated lysis of infected cells (8); iv) vif inhibits packaging of cellular cytidine 
deaminase apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G 
(APOBEC3G) into HIV virions, thereby increasing virus infectivity (9); v) vpr enhances 
nuclear transport of viral nucleic acids in non-dividing cells (10); and vi) vpu enhances 
virion release from infected cells and interacts with and induces CD4 degradation (11-
13). Genetic sequences termed long terminal repeats (LTR) flank the ends of the viral 
genome and play an important role in regulating viral gene expression and guiding 
integration into host cell DNA. 
I Vpr I lvpul 
5562 5853 6070 6302 
~ 
5834 6048 8368 8458 
I Gag 
------
793 5973 6048 8368 8663 
-
I Env I Net I 
636 6230 8805 8807 9431 
Figure 2. Genomic organization of HIV -1 [adapted from 
http://www .hiv .lanl.gov/content/hi v-db/MAP/hi vmap.html]. 
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1.2.4. IDV Replication 
Recognition of the target cell by mature mv virions occurs via an initial 
interaction between the envelope glycoprotein gp120 and the CD4 molecule (14-16). 
This interaction causes a conformational change that exposes multiple sites on gp120 (17, 
18) involved in binding to one of several chemokine receptors, including CCR5 or 
CXCR4 (19-21). Attachment of gp120 to its CD4 receptor and co-receptor induces 
further conformational changes in gp41, which promote fusion of viral and target cell 
membranes (22-24). 
Following entry and uncoating of the virus, reverse transcription begins within the 
nucleoprotein complex. The enzyme RT contains both polymerase and ribonuclease 
(RNase) H domains required for transcribing viral RNA into double stranded (ds) DNA. 
The polymerase domain consists of four subdomains referred to as "fingers", "palm", 
"thumb" and "connection" (25) which assume an "open right-hand configuration" to form 
the polymerase active site. Minus strand DNA synthesis is initiated using host-derived 
tRNALys packaged within mature mv virions as a primer. RNase H then cleaves viral 
RNA to remove it from the RNA-DNA hybrid and generate the primer used to initiate 
plus strand DNA synthesis. Completion of the plus strand DNA yields a complete 
dsDNA copy of the viral RNA. The nucleoprotein complex containing this dsDNA and 
the enzyme integrase enters the nucleus and facilitates integration of viral and host cell 
DNA. Ligation of the ends of viral and host DNA completes the irreversible integration 
process. Since transcription of proviral DNA does not usually occur in resting cells, 
integrated proviral DNA can remain latent indefinitely. 
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In activated cells, transcription of proviral DNA is mediated by host cell RNA 
polymerase II and results in production of both spliced and unspliced full-length 
transcripts which are transported to the cytoplasm for protein translation. Full-length 
transcripts encode gag and pol gene products and serve as genomic RNA for progeny 
virions while single and multiply spliced transcripts encode the remaining viral proteins 
(26-31). As mv viral proteins are synthesized and viral replication proceeds, full-length 
transcripts begin to accumulate within the cytoplasm for packaging into progeny virus. 
Protease is responsible for post-translational processing of GagPol polypeptides, which 
releases proteins required for virion assembly, while Gag directs budding of virus 
particles from the plasma membrane. 
1.3. Antiretroviral Therapy 
1.3.1. Protease Inhibitors 
Protease-mediated cleavage of GagPol polypeptides is essential for virion 
assembly and infectivity, thus rendering PR a key target for inhibition by antiretroviral 
drugs. Protease inhibitors (PI) target the active site of PR, a symmetrical homodimer with 
structural similarity to aspartyl proteases. 
1.3.2. Reverse Transcriptase Inhibitors 
Conversion of viral RNA into DNA by RT for subsequent integration into the host 
cell genome is another essential step in mv replication that is inhibited by drugs 
belonging to one of two classes of RT inhibitors: nucleoside reverse transcriptase 
inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). NRTI 
are chain terminating nucleoside analogues that compete with their natural counterparts 
for integration into nascent DNA (32). NNRTI inhibit RT by interacting with a pocket in 
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RT that is distinct from the active site, thus causing a conformational change in the 
polymerase active site which impairs enzyme function (33, 34). 
1.3.3. Fusion Inhibitors 
Since the fusion process is an essential part of the viral replication cycle it 
represents an additional target for inhibition of IllY replication. The only fusion inhibitor 
currently in clinical use is Enfuvirtide, also known as T-20, although additional synthetic 
peptides with similar function are being developed. Enfuvirtide is a synthetic peptide of 
the extracellular domain of gp41 and inhibits the conformational change required for 
fusion of viral and host cell membranes (35, 36). 
1.3.4. Integrase Inhibitors 
There are currently two classes of integrase inhibitors in development; the diketo 
acid inhibitors (DKA), which specifically inhibit the DNA strand transfer step of the IllY 
integration process and 5H-pyrano[2,3-d:-6,5-d'] dipyrimidines (PDPs), which interfere 
with formation of the DNA-integration complex (37-39). 
1.4. Immune Response to HIV 
1.4.1. Primary Infection 
During the initial stage of IllY infection, known as primary infection, viral RNA 
can be detected in the plasma of infected individuals within a few days of exposure to 
IllY. Clinical symptoms resembling mononucleosis often appear within 2 to 6 weeks 
(40). Primary infection is usually characterized by a massive burst in viremia and a 
marked increase in the level of circulating infected cells (41). Control of viremia during 
primary infection is mediated principally by CTL, since decrease in viremia occurs 
coincident with the emergence of anti-IllY CTL (42, 43) before neutralizing antibodies 
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are detectable (44). Despite this vigorous CTL response, HIV is not eliminated, although 
the amount of virus decreases and eventually stabilizes at a level referred to as the "viral 
set point". Viral set point is a strong predictor of the rate of clinical disease progression 
(45). 
1.4.2. Clinical Latency 
Establishment of the viral set point produces a prolonged asymptomatic period 
that can last several years. Although the level of HIV RNA remains undetectable in 
plasma, there is continuous low-level viral replication, as well as progressive loss of 
CD4+ T cells during this asymptomatic stage. Moreover, since HIV is able to establish 
latent infection by integrating into genomic DNA, reservoirs of latently infected cells 
allow HIV to survive indefinitely (46). 
1.4.3. Acquired Immune Deficiency Syndrome 
The final stage of HIV infection is characterized by a marked increase in virus 
load with viral replication occurring in both lymphoid and non-lymphoid tissues (47, 48). 
As the CD4+ T cell count falls below 200 cells /J..tl, clinical immunodeficiency becomes a 
greater risk and opportunistic infections are the eventual cause of death in most AIDS 
patients. 
1.4.4. Long-Term Non-Progressors 
Most untreated HIV -infected individuals eventually progress to AIDS, yet some 
individuals, termed long-term non-progressors (LTNP), are able to control virus and 
maintain high CD4+ T cell counts for prolonged periods in the absence of antiretroviral 
treatment (49). For some LTNP, attenuated disease course is due to polymorphisms in 
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IllV that diminish viral pathogenesis (50-53). However, infection with less virulent 
strains of mv does not account for most LTNP. Slow disease progression is more often 
linked with host genetic factors such as polymorphisms in the chemokine receptors used 
for entry by mv (54-56) or possession of specific human leukocyte antigen (HLA) 
alleles (57-59). The strong association between particular HLA class I alleles and slow 
disease progression suggests that CD8+ T cell recognition of mv antigens is crucial for 
immune control of mv. 
1.4.5. Resistance to HIV 
Anti-IDV CTL responses not only help control established mv infection but may 
also facilitate resistance to infection. IllV -specific CTL have been detected in individuals 
who apparently resist infection despite repeated exposure to mv (60-63). Resistance to 
mv has also been associated with IDV-specific humoral immunity (64-66) and in some 
instances with homozygosity for a 32-base pair deletion mutation in the CCR5 allele 
(~32-CCR5) that prevents cell-surface expression of the chemokine receptor used for 
entry by most primary isolates of mv (67, 68). However, since the frequency of 
homozygosity for ~32-CCR5 is approximately 1% in Caucasian populations and this 
mutated allele is absent in non-Caucasian populations, (69) ~32-CCR5 cannot account for 
the majority of individuals who resist mv infection. For this reason, there is a strong 
focus on identifying mv -specific CTL responses responsible for mediating resistance to 
mv infection and resistance to disease progression. 
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1.5. Viral Escape 
1.5.1. CTL Escape Mutations 
Since HIV -specific CTL play a crucial role in suppression of viremia, they exert 
strong selection pressure on the virus. Rapid virus turnover coupled with a highly error-
prone HIV RT that introduces approximately one nucleotide substitution per genome per 
replication cycle (70, 71) generally results in the emergence of CTL escape mutations. 
Mutations conferring escape from CTL may occur at sites that affect MHC binding (72), 
T cell receptor (TCR) recognition (73) or antigen processing (74) and can lead to loss of 
immune control of HIV (72, 75). 
1.5.2. Drug Resistance 
Uncontrolled viral replication also follows emergence of drug resistance 
mutations. NRTI were the first drugs used in mono or dual antiretroviral therapy to treat 
HIV. However, treatment often failed due to the rapid emergence of drug resistance 
mutations. With the introduction of NNRTI and PI, antiretroviral therapy (ART) was 
expanded to include combinations of three or more inhibitors. Treatment with a potent 
combination of anti-HIV compounds, also termed highly active antiretroviral therapy 
(HAART), was shown to reduce and maintain plasma viremia at undetectable levels for 
several years (76) and has now become the standard treatment for HIV -infected 
individuals. Unfortunately, prolonged exposure to HAART selects for drug resistance 
mutations which lead to viral rebound and progression to AIDS. During HAART, 
mutations that allow viral replication to continue in the presence of drugs are selected. 
Although these mutations may sometimes result in reduced viral fitness compared to 
wild-type virus, subsequent mutations compensating for any reduction in viral fitness are 
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also eventually selected. This results in high level resistance and or cross-resistance to 
multiple drugs, thus limiting the effectiveness of HAART. 
1.6. Study Objectives 
1.6.1. CTL Recognition of Drug Resistant illV 
While CTL responses and antiretroviral drugs are effective at controlling HIV 
replication, they ultimately fail to prevent disease progression when escape mutations 
emerge. The idea of more durably limiting viral replication by combining immune and 
drug selection pressures is supported by the strong selection for escape mutations that 
both CTL immune responses and antiretroviral inhibitors exert on HIV. Broadly cross-
reactive CTL responses have been associated with resistance to HIV infection and disease 
progression (77, 78), suggesting that pre-existing immunity against potential escape 
variants is key to long-term suppression of HIV replication. 
To establish whether immune and drug selection pressures converge in HIV 
infection, we tested how drug resistance mutations within HIV CTL epitopes affected 
their recognition by CTL. More specifically, we examined whether there was increased, 
decreased or sustained recognition of CTL epitopes incorporating drug resistance 
mutations compared with wild-type epitopes and investigated the ability of HIV -specific 
CTL to differentiate between wild-type and variant epitopes. We further examined viral 
sequences from individuals demonstrating CTL recognition of drug resistant HIV to 
assess whether recognition of epitopes incorporating drug resistance mutations was 
associated with the presence of specific mutations that elicited CTL specific for variant 
epitopes containing drug resistance mutations. 
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2. Antiretroviral Drug Resistance Mutations Sustain or Enhance CTL 
Recognition of Common IDV -1 Pol Epitopes 
2.1. Abstract 
Antiretroviral drug resistance and escape from eTL are major obstacles to 
effective control of HIV replication. To investigate the possibility of combining drug and 
immune-based selective pressures against HIV, we studied the effects of antiretroviral 
drug resistance mutations on eTL recognition of five HIV-1 Pol epitopes presented by 
common HLA molecules. We found that these common drug resistance mutations 
sustain or even enhance the antigenicity and immunogenicity of HIV-1 Pol eTL epitopes. 
Variable patterns of cross-reactive and selective recognition of wild-type and 
corresponding variant epitopes demonstrate a relatively diverse population of ens+ T 
cells reactive against these epitopes. Variant peptides with multiple drug resistance 
mutations still sustained eTL recognition, and some HIV -infected individuals 
demonstrated strong ens+ T cell responses against multiple eTL epitopes incorporating 
drug resistance mutations. Selective reactivity against variant peptides with drug 
resistance mutations reflected ongoing or previous exposure to the indicated drug, but 
was not dependent upon the predominance of the mutated sequence in endogenous virus. 
The frequency and diversity of eTL reactivity against the variant peptides incorporating 
drug resistance mutations and the ability of these peptides to activate and expand eTL 
precursors in vitro indicate a significant functional interface between the immune system 
and antiretroviral therapy. Thus, drug-resistant variants of HIV are susceptible to 
immune selective pressure that could be applied to combat transmission or emergence of 
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antiretroviral drug-resistant HIV strains and to enhance the immune response against 
HIV. 
2.2. Introduction 
The importance of CD8+ T cells in the immune response against HIV has been 
clearly established. Anti-HIV CTL are often detectable in highly exposed individuals 
resistant to HIV infection, long term nonprogressors maintain strong, diverse anti-HIV 
CTL responses, and in acute infection, emergence of HIV -specific CTL precedes a sharp 
decline in viremia (1-6). Selection of CTL escape mutants parallels rising virus loads in 
HIV and SIV infections, and when CD8+ T cell depletion before infection blunts CTL 
responses in SIV -infected monkeys, virus loads reach higher levels and remain high for a 
longer time (7-10). The immune system's disadvantage against a rapidly mutating virus 
is that it can only react to mutated peptide sequences after they emerge, whereas factors 
such as partial reactivity with altered peptide ligands and progressive immunodeficiency 
mitigate against efficient serial adaptation (11). Anticipating emerging mutants could 
reduce the disadvantage, but CTL escape mutations can vary widely within the agretope 
or epitope or even within flanking residues that affect protein processing (12, 13). 
Therefore, HIV escape from CTL can be relatively easily accomplished by various amino 
acid changes at loosely defined sites. 
Escape of HIV from antiretroviral drugs is a major obstacle to effective long term 
antiretroviral therapy. Mutations conferring resistance within one or more of the three 
most extensively used antiretroviral drug classes, NRTis, NNRTis, and Pis, have become 
increasingly common in clinical HIV isolates (14). Unlike the mutations allowing escape 
from CTL, drug resistance mutations localize to particular genomic sites and conform to 
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specific amino acid changes. Those conferring NRTI and NNRTI resistance cluster 
within RT codons 41-236, whereas those conferring PI resistance cluster within PR 
codons 10-90. These regions of HIV -1 Pol also encompass a number of previously 
identified CTL epitopes (15). If these CTL epitopes remain immunogenic after 
incorporating drug resistance mutations, the well-documented constraints on drug 
resistance mutations could potentially be exploited to prime the immune system in 
anticipation of emerging mutants. Furthermore, if any epitopes incorporating drug 
resistance mutations exhibit enhanced antigenicity or immunogenicity, this would suggest 
that drug treatment itself could modulate the CTL response against HIV. Therefore, we 
investigated how a number of common antiretroviral drug resistance mutations in HIV 
pol affect CTL recognition and how the relative reactivity of CTL against wild-type Pol 
peptides and their corresponding variants incorporating drug resistance mutations relate to 
treatment history and predominant endogenous viral sequences. 
2.3. Subjects and Methods 
2.3.1. Study population 
Our study cohort consisted of n=98 HIV -infected individuals attending the St. 
John's General Hospital HIV Clinic (St. John's, Newfoundland, Canada). HIV 
genotyping on selected plasma samples was conducted through a commercial service at 
the British Columbia Center for Excellence in HIV/ AIDS by reverse transcriptase-
polymerase chain reaction (RT -PCR) amplification and automated sequencing of the 
entire PR-encoding and first 400 codons of the RT-encoding HIV-1 pol gene segments 
(www.hivresistanceweb.com). Informed consent was obtained for blood collection and 
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access to antiretroviral treatment records. This study was given ethical approval by the 
Memorial University Faculty of Medicine Human Investigation Committee. 
2.3.2. Lymphocyte isolation and cell culture 
Whole blood was collected by venipuncture into acid-citrate-dextrose-treated 
Vacutainers (BD Labware, Franklin Lakes, NJ) and peripheral blood mononuclear cells 
(PBMC) were isolated with Ficoll-Paque Plus (Pharmacia Biotech, Uppsala, Sweden). 
Cells were washed twice with phosphate buffered saline (PBS) plus 1% fetal calf serum 
(FCS) and resuspended in medium consisting of RPMI 1640 with 10% FCS, 100 IU/ml 
penicillin, 100 J..Lg/ml streptomycin, 2 mM L-glutamine, 10 mM N-2-Hydroxyethyl-
piperazine-N'-2-Ethanesulfonic Acid (HEPES) buffer solution, and 2 X 10-5 M 2-
mercaptoethanol (ME) (all from Life Technologies Invitrogen, Grand Island, NY). HLA 
class 1-A and B type donors were determined as previously described (16) using 
commercial kits (One A.; Canoga, CA). Autologous B lymphoblastoid cell lines (BLCL) 
were generated by Epstein Barr virus (EBV) transformation of peripheral blood B cells. 
Briefly, 2.5 m1 of supernatant from marmoset B95-8 leukocytes (CRL 1612; American 
Type Culture Collection, Manassas, VA) was passed through a 0.45-J..Lm pore size sterile 
filter (Millipore, Bedford, MA) and added to 5 X 106 freshly isolated PBMC. These cells 
were then cultured for 24 h, washed, and maintained in medium with 20% FCS and 1 
J..Lg/ml cyclosporin A until sufficient growth occurred to cryopreserve several aliquots of 
the cell line. 
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2.3.3. Bulk anti-lllV CTL 
To activate bulk anti-HIV CTL, 1/lOth of an aliquot of freshly isolated PBMC 
was stimulated with 5 ).!g/ml purified phytohemagglutinin (PHA) (ICN Biomedicals, 
Aurora, OH) and 5 U/ml riL-2 (Hoffmann-LaRoche, Nutley, NJ) for 3 days, washed 
twice with PBS plus 1% FCS, and added to the remaining cells in medium. After 3-day 
coculture, 5 U/ml IL-2 was added, and after a further 7-day expansion, cells were tested 
for anti-HIV CTL. 
2.3.4. Enzyme-linked immunospot assay (ELISPOT) assay for IFN-y release 
Microtiter assay plates (Multiscreen; Millipore) were coated with 100 ).!1 of 15 
J.!g/ml anti-interferon-gamma (IFN-y) monoclonal antibody (mAb) 1-D1K (Mabtech, 
Stockholm, Sweden) overnight at 4°C. The plates were then washed six times with PBS, 
and PBMC were added in duplicate at 2 X 105 cells/well in medium together with 0.4 
J.!g/ml of the relevant peptide and incubated overnight. Negative control wells containing 
PBMC alone and PBMC plus control peptides known to bind to the HLA class I-A orB 
molecules presenting the test peptides were included. Positive control wells contained 4 
J.!g/ml PHA. All peptides were >95% pure (Genemed Synthesis, San Francisco, CA). 
After overnight incubation, plates were washed as described above, and 100 ).!Vwell of 1 
J.!g/ml biotinylated anti-IFN-y mAb 7-B6-1 (Mabtech) was added for 2 h. Wells were 
washed six more times, and 100 J.!l of streptavidin-alkaline phosphatase conjugate 
(Mabtech) diluted 111000 was added for 1 h. Plates were again washed six times, and 100 
J.!l chromogenic alkaline phosphatase substrate (Bio-Rad, Hercules, CA) diluted 1110 in 
Tris HCl buffer, pH 9.5, was added. After 30 min, plates were washed with tap water to 
terminate color reactions and then air-dried. Spots were counted with an automated 
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ELlS POT counter (Zellnet Consulting, New York, NY). Responses were considered 
positive if the number of spots was more than twice the negative control and >50/106 
PBMC. 
2.3.5. Peptide-specific CTL stimulation 
Peptide-specific CTL were generated in vitro as previously described (17). 
Briefly, 5 X 106 PBMC were pulsed with 100 J.LM peptide in 100 !J.l of medium for 1 hat 
37°C. The cells were then resuspended at 2.5 X 106 cells/ml in medium supplemented 
with 25 ng/ml recombinant human IL-7 (R&D Systems, Minneapolis, MN). On day 3, 10 
U/ml IL-2 was added, and cells were tested between days 10 and 14 for lysis of peptide-
pulsed BLCL. 
2.3.6. CTL assay 
Autologous BLCL were used as targets. To screen for anti-HIV Pol CTL, BLCL 
were infected for 16 h with 10 PFU/cell of a recombinant vaccinia virus, vCF21, 
expressing the entire HIV-1 HXB2 pol gene, or a control vaccinia virus, vSC8, expressing 
Escherichia coli ,8-galactosidase (18). Both viruses were from the National Institutes of 
Health AIDS Research Reference Reagent Program (Bethesda, MD). Infected cells were 
washed and incubated in 100 J.Ll of medium with 100 J.LCi of Na2 51Cr04 (Amersham 
Pharmacia Biotech, Piscataway, NJ) for 1 hat 37°C. Labeled cells were washed three 
times and transferred to U-bottom, 96-well plates (Corning Glass, Corning, NY) at 5 X 
103 cells/well. To test peptide-specific recognition, individual peptides were added in 
duplicate at a final concentration of 20 J.Lg/ml for 1 hat 37°C to 5 X 103 uninfected 
labeled target cells in 100 J.Ll of medium. Effector cells were added to the desired effector-
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to-target (E:T) cell ratios, and volumes were adjusted to 300 j..tllwell. Assays ran for 5 h, 
after which 125 ~-tl of supernatant/well was counted in a Wallac 1280 gamma counter 
(Gaithersburg, MD). Specific lysis was calculated as: (experimental 51 Cr release-
spontaneous 51Cr release)/(maximal 51 Cr release- spontaneous 51 Cr release) X 100. 
Spontaneous 51Cr release was <15% in all assays reported. 
2.4. Results 
2.4.1. Selection of illV-1 Pol CTL epitopes encompassing drug resistance mutations 
By overlaying common, well-defined antiretroviral drug resistance mutations onto 
mv CTL epitope maps, we found 11 previously known HIV Pol CTL epitopes in which 
drug resistance mutations occur (14). We focused on five epitopes restricted by the 
common lll..A molecules A2, A3, B35, and B44 (Fig. 2.1). More than 90% of the 
subjects in our cohort expressed at least one of these common lll..A class I alleles and 
many expressed two or more in combination. Therefore, these were the most practical 
epitopes with which to test the effects of the drug resistance mutations on immune 
recognition in our study cohort, and the results are applicable to the mv -infected 
population in general. The different drug resistance mutations incorporated into the 
variant peptides we selected for synthesis and testing collectively reflect the impact of 
multiple Pis, NRTis, and NNRTis. 
2.4.2. Recognition of peptides incorporating drug resistance mutations by bulk-
cultured anti-illV CTL 
As the selected peptides all derive from IDV-1 Pol, study subjects were initially 
tested for Pol-specific CTL using vCF21, a recombinant vaccinia virus expressing the 
entire HIV -1 clade B HXB2 Pol protein. We detected CTL against HXB2 Pol in >60% of 
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Schematic representation of regions of the mv -1 pol gene encoding known CTL epitopes that overlap with common 
drug resistance mutation sites. The HLA restriction of each epitope is indicated above the wild-type (top) sequence. Shaded 
segments of the pol gene indicate regions where most of the drug resistance mutations cluster. Shaded amino acids indicate 
mutations commonly selected for by antiretroviral drugs. These mutations were incorporated into synthetic variant peptides 
and tested for recognition. 
individuals tested (data not shown). Although recognition of epitopes containing drug 
resistance mutations need not correspond to recognition of this wild-type HIV laboratory 
strain Pol protein, peptide-specific CTL responses against our selected wild-type or 
variant Pol peptides were only detected in donors with Pol-specific CTL apparent using 
vCF21. 
When bulk-stimulated anti-HIV CTL from n=98 donors with the appropriate HLA 
were tested against peptide-pulsed BLCL, three of five wild-type peptides and variants of 
four wild-type peptides triggered specific cytolysis. Wild-type peptides RT33-41 (Fig. 
2.2a), RT107-115 (Fig. 2.2b), and RT203-212 (Fig. 2.2d) all triggered cytolysis by anti-
HIV CTL. Variant peptides incorporating one of the M41L, V108I, Y115F, Y181C, or 
L210W mutations also triggered cytolysis (Fig. 2.2). Variant peptides incorporating two 
mutations, V108I and Y115F (Fig. 2.2b) or Y181C and M184V (Fig. 2.2c), also triggered 
cytolysis. Thus, common antiretroviral drug resistance mutations within the four CTL 
epitopes, RT33-41, RT107-115, RT179-187, and RT203-212, presented by HLA-A3, 
B35, A2, and B44, respectively, sustain the antigenicity of these epitopes for HIV-
specific CTL. For RT107-115, recognition of wild-type and variant epitopes was cross-
reactive at the bulk CTL level (Fig. 2.2b). For the RT33-41 and RT203-212 epitopes, 
there were instances of cross-reactive recognition of wild-type and variant peptides (Fig. 
2.2a and d, subjects 121 and 131) and selective recognition of either the wild-type or 
variant peptide (Fig. 2.2a and d, subjects 012, 055, 057, 077, 082, and 126). For the 
RT179-187 epitope, selective recognition of variant peptides incorporating the Y181C 
(Fig. 2.2c, donor 028) or Y181C and M184V (Fig. 2.2c, donor 001) mutations occurred. 
These data indicate a complex CTL repertoire capable of recognizing HIV-1 Pol epitope 
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variants incorporating common drug resistance mutations and, in some cases, of 
distinguishing the variants from their wild-type counterparts. 
2.4.3. IFN-y production by PBMC exposed to peptides incorporating drug 
resistance mutations 
As IFN-y ELISPOT assays are sensitive and can estimate the frequency of 
peptide-specific T cells in unmanipulated PBMC, we tested freshly isolated or 
cryopreserved PBMC by ELISPOT for recognition of IITV-1 Pol CTL epitopes 
incorporating drug resistance mutations. The same three wild-type peptides and 
corresponding variants that triggered cytolysis by bulk-stimulated anti-IITV CTL 
stimulated IFN-y-release from PBMC and recognition of the RT33-41 wild-type and 
M41L variant was detected in the context of Ill..A-A2 (Fig. 2.3a-d). In addition, both the 
PR76-84 wildtype epitope and I84V drug resistance mutation variant stimulated IFN-y 
release (Fig. 2.3e). ELISPOT recognition patterns with PBMC were similar to those 
observed in lytic assays with bulk-stimulated anti-IITV CTL. Recognition of RT107-115 
and PR76-84 wild-type epitopes and their corresponding drug resistance variants was 
cross-reactive (Fig. 2.3, c and e), whereas RT33-41 and RT203-212 wild-type and drug 
resistance variant peptides showed cross-reactive (Fig. 2.3a, subjects 001,007,062, and 
134; Fig. 2.3b, subjects 121 and 162; Fig. 2.3d, subjects 077 and 134) and selective 
recognition (Fig. 2.3a, subjects 043, and 131; Fig. 2.3b, subjects 077, 082, and 147; Fig. 
2.3d, subjects 017,055, 057, 118, and 131). Cross-reactivity of the RT107-115 and 
PR76-84 wild-type and variant peptide epitopes was confirmed across a range of peptide 
concentrations from 4 ~M to 400 pM (Fig. 2.4a and b). These ELISPOT data demonstrate 
a complex circulating T cell repertoire with CTL precursors capable of recognizing 
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Figure 2.3 
Peptide-specific stimulation ofiFN-y release in PBMC from HIV-
infected individuals by wild-type Pol peptides and variants 
incorporating drug resistance mutations. Unshaded bars show 
background spot-forming cells (SFC). The number of SFC triggered by 
wild-type and corresponding variant peptides RT33-41 (a and b), 
RT107-115 (c), RT203-212 (d), and PR76-84 (e) are shown with 
hatched or dark bars, with specific mutations indicated in the legend. 
The dashed line at 50 SFC/106 PBMC represents the lower limit for a 
positive response. 
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HIV -1 Pol epitope variants incorporating common drug resistance mutations and, in some 
cases, distinguishing them from their wild-type counterparts. ELISPOT assays were 
repeated at several time points for most individuals. Although the absolute number of 
spot-forming cells changed over time, the reactivity patterns for the wild-type and variant 
peptides remained consistent, and representative data are shown. 
The ELISPOT data clearly demonstrated recognition of peptides incorporating 
drug resistance mutations by circulating T cells from HIV -infected individuals. The 
hierarchy of epitopes recognized and the pattern of cross-reactivity between wild-type 
and corresponding variant peptides reflected those seen with bulk-cultured anti-HIV CTL. 
The peptide-specific T cell frequencies observed illustrate the antigenicity and suggest in 
vivo immunogenicity of variant peptides incorporating drug resistance mutations. 
Notably, the frequency ofT cells producing IFN-y in response to the RT33-41(M41L) 
variant peptide presented in the context of HLA-A3 reached -11200 PBMC, roughly 1% 
of circulating CDS+ T cells (Fig. 2.3b ). Most responding cells in this case did not cross-
react with wild-type RT33-41, suggesting selective in vivo induction of high frequency 
CTL against viral variants incorporating the M41L drug resistance mutation. 
2.4.4. Relationship among CTL specificity, treatment history, and HIV genotype 
HIV genotypic information was obtained from each subject with plasma virus load 
>1000 RNA copies/ml to assess the relationship between predominant endogenous viral 
sequences at the time of testing, treatment history or current status, and specificity of anti-
HIV CTL for wild-type or variant peptides. In some cases, genotypic information could 
not be obtained at all or could not be obtained coincident with immunological testing 
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because of undetectable plasma virus loads, but information was always taken from the 
closest feasible time point. Complete antiretroviral treatment history was available for all 
study participants. Relevant genotypic and treatment history information is summarized 
in Table 2.1. As there was CTL cross-reactivity for the PR76-84 and RT107-115 wild-
type and variant peptides over a range of peptide concentrations (Fig. 2.4), neither the 
predominant endogenous sequence nor the treatment history can impact on CTL 
specificity. However, there could be in vivo selection for or against different endogenous 
variants by the CTL. Sequence information was only available for subject 082 with CTL 
against RT107-115 wild-type and variant peptides associated with NNRTI and abacavir 
(ABC) resistance. Although he was receiving the NNRTI sustiva and had a high plasma 
virus load, no mutations associated with NNRTI or ABC resistance were detected within 
RT107-115 at the time the CTL assay shown in Fig. 2.2b was performed. 
Sequence information was available for subjects 001, 065, and 078 with CTL 
against PR76-84. All were receiving Pis at the time of testing, and the I84V mutation 
was predominant in subjects 065 and 078. This shows that the HLA-A2-restricted PR76-
84 peptide with or without the drug resistance-associated mutation I84V can persist in 
endogenous virus in the face of a specific CTL response. The genotype for endogenous 
virus of subjects 001 and 065 was obtained from the same time point as the ELISPOT 
data, whereas the closest sample from subject 078 with a detectable plasma virus load 
was taken 18 months before the ELISPOT. 
As CDS+ T cells responding to RT33-41, RT179-187, and RT203-212 were only 
partially cross-reactive with wild-type and variant peptides, we expected to see some 
impact of treatment history and predominant endogenous viral sequence on relative levels 
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Table 2.1. Treatment History and Endogenous Viral Sequence of Individuals with 
CDS+ T cell Recognition of Epitopes Incorporating Antiretroviral Drug Resistance 
Mutations 
Subject Recent Treatment History HIV genotype 
001 DDI, 3TC, ABC, amprenavir (1 0/00-present) RT M41L, M184V 
DDI, d4T, sustiva, ritonavir, indinavir (6/99-10/00) RTM41L 
012 d4T, 3TC, sustiva (9/99-present) RTL210 
017 d4T, 3TC (11/98-present) Virus load too low 
028 3TC, sustiva, nelfinavir (6/99-present) Virus load too low 
039 AZT, 3TC, ritonavir, saquinavir (11100-present) Virus load too low 
043 d4T, 3TC, DDC (2/99-present) Virus load too low 
055 sustiva, saquinavir, ritonavir (5/00-present) Virus load too low 
ABC, saquinavir, ritonavir (1/99-5/00) 
057 Nil (7/01-present) 3TC, d4T saquinavir (8/97-7/01) PR 184V 
062 DDI, d4T, sustiva (7/01-present) RTM41L 
065 3TC, ABC, sustiva (8/00-present) PR 184V 
d4T, DDI, indinavir (3/98-8/00) 
077 Nil (7/02-present), 3TC, d4T (5/01-7/02) RTM41, L210 
078 3TC, d4T, kaletra (3/02-present) Nil (5/00-3/02) PRI84 
081 DDI, d4T, ritonavir, saquinavir (9/99-present) Virus load too low 
082 DDI, ABC, kaletra (2/02-present) RT M41, Vl08, Y115 
DDI, d4T sustiva (7/99-2/02) 
118 AZT, 3TC, indinavir (4/99-present) Virus load too low 
121 AZT, 3TC, ABC 0/02-present) Virus load too low 
Nevirapine, 3TC, ABC (6/00- 0/02) 
126 AZT, 3TC, sustiva (5/99-present) Virus load too low 
131 3TC, d4T, sustiva (6/00-present) Virus load too low 
134 d4T, 3TC, sustiva (10/99-present) Virus load too low 
147 3TC, ABC, sustiva (5/00-present) Virus load too low 
162 AZT, 3TC, sustiva (4/02-present) RT M41, V108, Y115 
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of reactivity of these CTL against wild-type and variant peptides. The RT33-41 wild-
type and M41L variant peptides were recognized in the context of 6 Ill..A-A2 subjects 
(Fig. 2.3a) and in the context of 5 Ill..A-A3 subjects (Figs. 2.2a and 2.3b) with 
differential skewing toward either wild-type or mutant peptide. 
Recognition of the wild-type RT33-41 peptide and M41L variant associated with 
azidothymidine (AZT) and stavudine (d4T) resistance was mixed for the six Ill..A-A2 
individuals (Fig. 2.3a). Subject 001 was receiving abacavir (ABC), and the rest were 
receiving d4T at the time of testing. Although ABC does not select for the M41L 
mutation, once acquired this mutation can contribute to ABC resistance 
(www.hivresistanceweb.com). Subject 001 had previously been treated with d4T and 
AZT and acquired the M41L mutation before ABC treatment. Sequence data coincident 
with the ELISPOT results were available for 001 and 062, both of whom had 
predominant M41L mutant endogenous virus. Sequence data from subject 007 could 
only be obtained from a plasma sample taken 18 mo before the ELISPOT, which showed 
predominantly M41 wild-type virus. These results suggest that exposure to AZT or d4T 
sensitizes CD8+ T cells from Ill..A-A2 individuals against the RT33-41 peptide epitope 
containing the M41L resistance-associated mutation and show that the epitope containing 
the M41L mutation persists in the face of this HLA-A2-restricted immune response. 
Recognition of the variant peptide incorporating the M41L mutation was 
predominant for four of the five Ill..A-A3 subjects (Fig. 2.3b). One subject (121) was 
receiving AZT at the time of testing. The others were receiving d4T (077), AZT (162), or 
ABC (082 and 147) at the time of testing. Subject 082 had been receiving d4T until 
within 1 month of the CTL assay shown in Fig. 2.2a and until within 6 months of the 
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ELISPOT assay. Subject 147 had received AZT and d4T in the past, but not within 18 
months of the ELISPOT assay. Endogenous viral sequence data for subject 082 revealed 
wild-type RT33-41 as the predominant endogenous species. Subject 162, who was the 
only HLA-A3 subject to preferentially recognize the wild-type sequence, had started 
antiretroviral therapy with AZT, larnivudine (3TC), and sustiva only 1 month before 
testing. His predominant endogenous viral sequence was also wild-type. These results 
suggest that exposure to AZT or d4T sensitizes IllV -infected HLA-A3 individuals against 
the RT33-41 peptide epitope containing the M41L resistance-associated mutation. This 
sensitization persists without predominance of the mutation in endogenous virus. In 
contrast to the HLA-A2 subjects, the M41L mutation was not seen in any of the three 
HLA-A3 individuals with a CDS+ T cell response against the RT33-41 M41L variant 
epitope for whom genotypic information was available. 
With the RT179-187 epitope, we saw exclusive recognition of peptides 
incorporating resistance mutations by two individuals (Fig. 2.2c). Subject 028, who was 
receiving the NNRTI sustiva, recognized a peptide with NNRTI-associated mutation 
Y181C. Subject 001, who was receiving the NRTis didanosine, larnivudine, and ABC, 
recognized a peptide with both Y181C and M184V mutations. The M184V mutation is 
associated with 3TC, didanosine (DDI), zalcitabine (DDC), and ABC resistance. His 
predominant endogenous virus at the time incorporated the M184V mutation, but not 
Y181C, and he had not received NNRTis within 4 years of testing. 
All seven individuals who recognized the RT203-212 epitope preferentially 
recognized the wild-type epitope over that incorporating the L210W mutation (Fig. 2.3d). 
The L210W mutation, like M41L, is selected for by AZT and d4T, but can also contribute 
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to ABC resistance, once established. Both subjects (077 and 134) who showed some 
recognition of the mutant epitope were receiving d4T. Two individuals who exclusively 
recognized the wild-type epitope had either never received AZT or d4T (055) or had not 
received either of these drugs for at least 2 years (057). The endogenous viral sequence 
from subject 057 from a sample taken nearly 1 year after the ELISPOT assay was 
predominantly wild-type within RT203-212. Three other Ill.-A-B44 individuals who 
exclusively recognized the wild-type epitope were nonetheless receiving d4T (017 and 
131) or AZT (118). Thus, it appears that exposure to AZT or d4T can sensitize Ill.-A-B44 
individuals to a variant peptide epitope incorporating the L210W mutation, but that this 
variant is less immunogenic than the wild-type epitope. 
2.4.5. Peptide-specific CTL stimulation 
The ability of wild-type and variant peptides to activate CTL in vitro was tested by 
peptide-specific PBMC stimulation. Although all peptides were antigenic, 
the pattern of in vitro activation of self-reactive versus cross-reactive CTL varied for 
individual peptides (Fig. 2.5). For Ill.-A-A3+ subject 082, the RT33-41 M41L variant 
activated CTL specific for itself without cross-reactivity for the wild-type RT33-41 
peptide, whereas the wild-type peptide activated no CTL against itself or the variant (Fig. 
2.5a). This reflected the selective recognition of the variant peptide that we observed by 
bulk cytotoxicity and ELISPOT (Figs. 2.2a and 2.3b). Subject 162 showed the same 
response pattern as 082 after re-stimulation (data not shown), which did not match the 
ELISPOT data showing preferential recognition of the wild-type peptide, but did match 
the apparently enhanced in vitro immunogenicity of the M41L variant overall. In the 
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context of Ill..A-A2, both the wild-type and variant peptides stimulated CTL from 
subjects 043 (Fig. 2.5b), 001, 007, and 134 (data not shown), who were cross-reactive for 
both peptides. This matches the generally cross-reactive recognition of both the wild-
type and variant peptides seen in the ELISPOT assays. For subjects 126 (Fig. 2.5c) 017, 
055, and 131 (data not shown), the wild-type RT203-212 peptide activated CTL cross-
reactive against itself and the L210W variant peptide, whereas the L210W variant did not 
activate CTL against either peptide. This matched the ELISPOT data in that reactivity 
against the wild-type peptide was favored, but the wild-type peptide stimulated CTL 
against the L210 variant even in subjects who showed no significant reactivity with the 
L210W variant peptide by ELISPOT. For subject 039, both the wild-type PR76-84 and 
184V variant peptide induced CTL cross-reactive against both peptides (Fig. 2.5d), 
matching the ELISPOT data showing complete cross-reactivity between the wild-type 
and 184V variant peptides. Overall, the peptide stimulation results indicate that for the 
Ill..A-A3-restricted RT33-41 and Ill..A-B44-restricted RT203-212 epitopes, the reactive 
T cell population in IDV-infected individuals includes T cells that distinguish between 
wild-type and variant peptides and T cells that cross-react with both wild-type epitopes 
and variants incorporating drug resistance mutations. For the Ill..A-A2-restricted RT33-
41 and PR76-84 peptides, T cells appear to predominantly cross-react with the wild-type 
and variant peptides. 
2.5. Discussion 
In this study we examined the effect of antiretroviral drug resistance-associated 
mutations on recognition of mv -1 Pol CTL epitopes presented by common Ill..A 
molecules. Although cross-reactivity patterns differed, variant peptides incorporating 
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common mutations associated with the three major antiretroviral drug classes all 
sustained and in some cases even enhanced T cell recognition. Recognition of the wild-
type and variant peptides encompassing sites of common drug resistance mutations was 
quite prevalent in our study cohort with relatively high frequencies of reactive T cells. It 
was not uncommon for individuals to show T cell reactivity against multiple epitopes 
potentially or actually incorporating drug resistance mutations, indicating a strong 
immunological focus on functional determinants of the HIV Pol proteins. 
We saw several patterns in terms of relative recognition and in vitro 
immunogenicity levels of wild-type and variant peptides that in most cases reflected 
antiretroviral treatment history. In the case of the HLA-A2-restricted PR76-84 and HLA-
B35-restricted RT107-115 epitopes, recognition and immunogenicity patterns were 
independent of treatment history due to the complete cross-reactivity of the wild-type and 
variant peptides. The HLA-B44-restricted RT203-212 wild-type epitope was always 
preferentially recognized relative to the L210W variant, and the variant was only 
recognized by individuals who had been treated at some point with antiretrovirals known 
to select for the L210W mutation. Despite the apparent in vivo immunogenicity of the 
L210W variant peptide, it failed to expand CTL against itself in vitro, whereas with 
PBMC from individuals sensitized in vivo against the L210W peptide, the wild-type 
peptide expanded CTL against itself and the L210W variant. Although this might suggest 
immunological selection against the wild-type sequence in HLA-B44 individuals, we did 
not observe the L210W mutation in any of 3 HLA-B44 individuals for whom viral 
sequence data were available regardless of their ongoing or previous antiretroviral 
treatment. 
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The HLA-A3-restricted RT33-41 epitope exhibited the most interesting pattern of 
recognition and immunogenicity. Although there was some cross-reactivity, the M41L 
variant peptide was nearly always preferentially recognized by CTL or PBMC from HIV-
infected individuals currently or previously receiving antiretrovirals selecting for the 
mutation. This preferential recognition pattern, sustained even in the absence of in vivo 
M41L predominance, suggests that the M41L mutation increases the immunogenicity of 
this epitope in vivo. In vitro activation and expansion of CTL reinforced this suggestion, 
as the M41L variant peptide activated CTL against itself, but not the wild-type peptide, 
whereas the wild-type peptide was non-immunogenic in vitro, even with PBMC from 
individuals preferentially recognizing the wild-type peptide. Preferential recognition and 
enhanced immunogenicity ofRT33-41 incorporating the M41L mutation raise the 
possibility of immunological selection against this drug resistance-associated mutation in 
vivo in HLA-A3 individuals. Despite an overall high frequency of the M41L mutation, 
this mutation was only seen in two HLA-A3 individuals in our cohort, both of whom 
were severely immunodeficient with no residual CDS+ T cell response against HIV 
detectable. This contrasts with the RT33-41 epitope presented in the context of HLA-A2, 
where recognition of both the wild-type peptide and the M41L variant is common, with 
no general preference observed, and both peptides activate and expand CTL against 
themselves and the corresponding variant in vitro. Consistent with this apparent 
relatively equal immunogenicity, the M41L mutation was seen in two of the HLA-A2 
individuals with CDS+ T cells against this epitope, suggesting no immunological selection 
against either variant. Longitudinal studies of a larger number of HLA-A2 and A3 
individuals with CDS+ T cell responses against RT33-41 could best evaluate 
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immunological selection against the M41L mutation associated with AZT and d4T 
resistance. Of note in this regard was the endogenous viral sequence of subject 082. 
Despite his preferential recognition of RT33~1 incorporating the M41L mutation, 
sequencing of endogenous virus at six historical time points spanning >6 years revealed 
no M41L mutations. However, over the last four time points covering 4 years, the T215Y 
mutation was present (data not shown). Together with the M41L mutation, T215Y or 
T215F confers high level resistance to AZT or d4T, and therefore, these mutations almost 
always occur in tandem (www.hivresistanceweb.com). Subject 082 was unique among 10 
individuals with T215Y/F in our cohort in the absence of the complementary M41L 
mutation in the predominant endogenous virus. The M41L mutation never occurred in 
the absence of the complementary T215Y/F mutation . Although more studies are 
necessary to prove this point, these results suggest that the M41L mutation in the context 
of HLA-A3 can be immunogenic when present at levels below which it is detectable by 
commercial genotyping methods and that this immune response exerts selective pressure 
against accumulation of the mutation and emergence of high level AZT and d4T 
resistance. 
Although the effects on immunogenicity of the variants are neutral, positive, or 
negative, respectively, the HLA-A2-restricted RT33~1, HLA-A3-restricted RT33~1, 
and HLA-B44-restricted RT203-212 drug resistance variant recognition patterns 
demonstrate a complex available T cell repertoire of CDS+ T cells, some cross-reactive 
and some specific for particular variants. Previous studies have shown recognition of 
peptides incorporating drug resistance mutations that in at least some cases was specific 
for the variant incorporating the drug resistance mutation (19-21). Both cross-reactive 
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recognition and specific recognition of drug resistance associated variant peptides offer 
opportunities for exploitation of the available CD8+ T cell repertoire, especially when the 
variant peptides have enhanced immunogenicity. For example, the general cross-
reactivity of the Ill-A-A2-restricted RT33-41 and PR76-84 and the Ill-A-B35-restricted 
RT107-115 variants implies that these peptides could be used therapeutically to boost 
immunity against both wild-type virus and drug-resistant variants. Inclusion of such 
epitopes in prophylactic vaccines would potentially offer coverage against both wild-type 
HIV and the drug-resistant HIV strains now being transmitted with increasing frequency 
(22, 23). The partially selective recognition of other drug resistance-associated CTL 
epitopes offers different opportunities. Firstly, as the T cell populations recognizing the 
wild-type and variant peptides are not completely overlapping, it implies the variants 
could be used to both strengthen and diversify the CTL response against HIV. 
Diversification to include CTL responses selective for drug-resistant HIV might be 
especially effective if evoked before using antiretroviral drugs selecting mutations 
represented in the variant epitopes used for immunization. Pre-existing immunity against 
drug-resistant viruses present at low frequencies, if present at all, should delay the 
emergence of drug resistance. Another implication of selective recognition of M41L and 
L210W mutation-incorporating variants is an opportunity to strengthen and diversify the 
anti-HIV CTL response through novel forms of autoimmunization without treatment 
interruption. Both mutations reflect the selective impact of AZT and d4T; therefore, 
manipulating the relative dominance of endogenous viral variants by cyclical 
administration and withdrawal of one or both of these drugs could augment immunity 
against both wild-type and drug-resistant HIV. 
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Documenting the antigenicity and immunogenicity of CTL epitopes incorporating 
antiretroviral drug resistance mutations is a first step toward developing immune 
strategies against the emergence and transmission of drug-resistant mv. Although the 
immunogenicity of these epitopes is fundamental, a number of additional factors will 
determine the antiviral efficacy of CTL they might induce. Pol is a major T cell antigen 
in human IDV infection, and importantly, Ill..A-associated selection for sequence 
variation within Pol CTL epitopes demonstrates selective pressure of anti-IDV Pol CTL 
in vivo (24-26). In humans and macaques, CTL activity against just one epitope can 
sustain relative viral quiescence and slow disease progression (9, 10). The five CTL 
epitopes and corresponding drug resistance variants we tested are presented by Ill..A-A2, 
-A3, -B35, and -B44, four alleles that together cover >90% of people of western 
European descent and a majority of most other ethnic populations. Other CTL epitopes 
with drug resistance mutations are known, and more almost certainly remain to be 
identified (19-21). Thus, broadly applicable multiepitope vaccines against drug-resistant 
mv are feasible. 
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3. Cross-reactive CTL Against IDV-1 PR and IFN-y-Inducible Protein 30 
3.1. Abstract 
The IFN-y-inducible protein (IP)-30 signal peptide -11 to -3 (LLDVPT AA V) is a 
prominent self peptide expressed with the class I HLA-A2. Stimulation of PBMC from 
HLA-A2 IDV-1-infected individuals with an HLA-A2-restricted IllV protease (PR) 
peptide 76-84 (LVGPTPVNI) activated CTL against the IP-30 signal peptide. Since 
IDV-1 PR 76-84 stimulated CD8+ T cells from these individuals to secrete IFN-y, we 
tested whether the activation of IP-30-specific CTL in vitro resulted from T cell cross-
reactivity or from up-regulation of IP-30 by IFN-y. Neither high levels of exogenous 
IFN-y, nor incubation of PBMC with other mv peptides triggering substantial IFN-y 
release activated IP-30 specific CTL. Although the IP-30 signal peptide did not stimulate 
IFN-y release from freshly-isolated PBMC, it activated CTL in vitro against itself and 
mv PR 76-84. Peptide- stimulated IFN-y release, cold target inhibition, and HLA-A2/Ig 
dimer-mediated binding and depletion of effector cells all indicated that in vitro 
stimulation with IDV PR 76-84 or the IP-30 signal peptide activated a comparable 
population of cross-reactive effector cells. Neither IP-30 nor mv PR 76-84 activated 
CTL against themselves following in vitro stimulation of PBMC from non-IDV -infected 
HLA-A2 individuals. Peptide titrations indicated higher avidity T cell interactions with 
IllV PR 76-84 than with the IP-30 signal peptide. These data indicate that IllV PR76-84 
is a heteroclitic variant of the IP-30 signal peptide -11 to -3, which has implications for 
immune memory and autoimmunity. 
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3.2. Introduction 
Viral infections can trigger immunopathology or autoimmunity through a variety 
of mechanisms. Immunopathology results when the antiviral immune response targeting 
infected or otherwise sensitized host cells damages self tissues, such as in viral hepatitis. 
Autoimmunity results from the selective activation and expansion of normally quiescent 
self-reactive B or T lymphocytes. Molecular mimicry between viral and self-proteins, 
selective up-regulation of certain host proteins, virus-induced changes in the processing 
of host-proteins, enhanced antigen presenting cell (APC) function and pro-inflammatory 
environmental conditioning can all facilitate induction of autoimmunity or 
immunopathology by viral infections (1-8). While even acute infections can trigger 
immunopathology and autoimmunity, the persistent influence of chronic viral infections 
increases the probability of these immunological side-effects. 
HIV-1 establishes chronic infection in essentially 100% of cases and has been 
associated with both immunopathology and autoimmunity. Immunopathology related to 
the pronounced CD8+ T cell activation characteristic of HIV infection includes skin 
rashes, alveolitis, sicca-syndrome, lymphadenopathy, neuritis and vasculitis (9-14). 
Autoreactive CD8+ T cells specific for self-peptides selectively overexpressed in HIV-
infected cells have also been identified in HIV-infected individuals (15,16). In this 
context, both the pro-immune cytokine IFN-y itself and a number of IFN-y-responsive 
genes are expressed at elevated levels in lymphatic tissue when HIV replication is not 
fully suppressed (17). This alters the protein expression pattern and enhances the antigen-
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presenting capacity of IFN-y responsive cells, which could subsequently favor activation 
of cross-reactive T cells against IFN-y-inducible proteins. 
The signal peptide -11 to -3 (LLDVPTAA V) from an IFN-y-inducible protein (IP) 
termed IP-30 is a dominant self-peptide expressed in the context of lll..A-A2 (1S). IP-30 
was originally identified as an IFN-y-inducible protein ubiquitously expressed in IFN-y-
stimulated PBMe and distributed in the lysosomes (19). More recently, IP-30 was shown 
to localize within MHe class II compartments (Mile) (20) and therein catalyze reduction 
of disulfide bonds in proteins endocytosed by APe (21). Therefore, IP-30 is also referred 
to as y-IFN-inducible lysosomal thiol reductase (GILT). Due to the central role of IP-30 
in antigen processing and presentation and the prominent expression of the IP-30 signal 
peptide in the context of HLA-A2, we reasoned that T cell tolerance would be strictly 
enforced against the IP-30 signal peptide and chose it as a control HLA-A2 binding 
peptide for studying HIV -specific HLA-A2-restricted ens+ T cell responses. Although 
we never observed ex vivo IFN-y release by ens+ T cells in response to the IP-30 signal 
peptide, eTL against HLA-A2 target cells pulsed with IP-30 signal peptide arose 
following in vitro stimulation of PBMC with the HIV PR peptide 76-S4 (L VGPTPVNI). 
Since activation of IP-30-specific eTL was associated with strong ex vivo IFN-y release 
in response to the PR 76-S4 peptide and IFN-y increases IP-30 expression levels, we 
tested whether in vitro induction of IP-30 signal peptide-specific CTL by HIV PR 76-S4 
reflected the impact of elevated IFN-y levels or cross-reactivity between the 2 peptides. 
We found that in HIV-infected HLA-A2 individuals, the ens+ T cell response against 
HIV PR 76-S4 included self-reactive ens+ T cells specific for the IP-30 signal peptide. 
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These cross-reactive CTL were readily activated in vitro by either mv PR 76-84 or the 
IP-30 signal peptide itself. The IP-30 signal peptide also activated CTL in vitro against 
IDV PR 76-84. Such cross-reactivity may have both pathological potential, in the context 
of autoimmunity against APC, and adaptive potential in the context of an IFN-y 
responsive self-peptide acting as a surrogate peptide supporting the maintenance or 
propagation of a select subset of anti-viral CTL. 
3.3. Materials and Methods 
3.3.1. Study population 
Subjects for this study were a subset of HLA-A2 individuals nested within a study 
cohort of IDV -infected individuals attending the St. John's General Hospital IDV Clinic, 
St. John's, Newfoundland, Canada. Laboratory personnel expressing HLA-A2 served as 
non-IDV-infected controls. Informed consent was obtained for blood collection and this 
study was given ethical approval by the Memorial University Faculty of Medicine Human 
Investigation Committee. Blood was drawn concurrently for these studies and for 
standard clinical follow-up, which included plasma virus load measurement, blood 
chemistry, and lymphocyte subset analysis. 
3.3.2. Lymphocyte isolation and cell culture 
As outlined in section 2.3.2. 
3.3.3. IFN -y ELISPOT assay 
As outlined in section 2.3.4. 
3.3.4. Peptide-specific CTL stimulation 
As outlined in section 2.3 .5. 
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3.3.5. CTL assay 
As outlined in section 2.3.6. 
3.3.6. Intracellular flow cytometry 
Stimulator cells were generated by incubating 1.0 X 105 BLCL for 1 hr with 20 
J..tM peptide at 37°C, 5% C02 for 1 h. BLCL incubated as above without peptide served 
as negative controls. Peptide-stimulated CTL were added to the stimulator cells at a 5:1 
ratio and incubated 5 h at 37°C, 5% C02. Brefeldin A (Sigma-Aldrich, Oakville, ON, 
Canada) was added to cells for the final4 hat 10 J..tg/ml. Cells were then washed with 
fluorescence-activated cell sorting (FACS) buffer containing 5 mM ethylenediamine-
tetraacetic acid (EDT A), 0.5% bovine serum albumin (BSA), 0.02% sodium azide (all 
from Sigma) in PBS, incubated with phycoerythrin (PE)-labeled anti-human CDS (Caltag, 
Hornby, ON, Canada) at 4°C for 20 min and then washed again with FACS buffer. Cells 
were then fixed with Fixation Buffer A (DAKO Cytomation Inc., Mississauga, ON, 
Canada), permeabilized with Perm Buffer (DAKO) and incubated with fluorescein 
isothiocyanate (FITC)-conjugated mouse anti-IFN-y mAb (Caltag) at 4°C for 20 min. 
The cells were then washed, resuspended in 1% paraformaldehyde and analyzed on a 
FACSCalibur flow cytometer. 
3.3.7. Flow cytometry and T cell depletion with HLA-A2:Ig dimer 
Empty HLA-A2:Ig dimer protein (BD Biosciences Pharmingen, Mississauga, ON, 
Canada) was loaded with peptide as per manufacturer's instructions. Briefly, HLA-A2:Ig 
dimer was mixed with 160M excess peptide in PBS, pH 7.2 and incubated overnight at 
37°C. Lyophilized peptides were dissolved at 50 mg/ml in DMSO and diluted 1:25 in 
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sterile PBS, pH 7.2. Empty Ill..A-A2:Ig dimer served as a negative control. Peptide 
stimulated PBMC (CTL lines) were incubated at 1 X 106 cells per 50 J..IL FACS buffer 
with 8 !J.l FeR blocking reagent (Miltenyi Biotec, Auburn, CA) at 24°C for 10 min. After 
this, 2!-lg peptide-loaded Ill..A-A2:Ig dimer was added and the cells were incubated at 
4°C for 1 hour. Cells were then washed twice with FACS buffer followed by a second 
incubation with 8 !J.l FeR blocking reagent (Miltenyi) at 24°C for 10 min. PE-conjugated 
A85-1 mAb (rat anti-mouse IgG1) (BD Biosciences Pharmingen) was then added and 
cells were incubated at 4°C for 30 min. The cells were then washed twice in FACS buffer 
and resuspended in 1% paraformaldehyde for analysis on a FACSCalibur flow cytometer 
(BD Biosciences). 
For depletion experiments, cells were incubated with peptide-loaded Ill..A-A2:Ig 
dimer as above, washed in PBS supplemented with 0.5% BSA and 2 mM EDTA, pH 7.2, 
and incubated with a 10:1 ratio of goat anti-mouse IgG-coated magnetic beads (Dynal 
Inc, Brown Deer, WI, USA) at 4°C for 45 min. Bead-bound cells were removed by 
magnetic attraction and the unbound cells tested for cytotoxicity against selected target 
cells. 
3.4. Results 
3.4.1. IDV PR 76-84 activates CTL against the IP-30 signal sequence peptide in 
IDV-infected individuals expressing HLA-A2 
We originally chose the HIV PR 76-84 peptide LVGPTPVNI for in vitro 
stimulation of CTL in order to study cross-reactivity between this peptide and a variant 
incorporating the I84V mutation associated with HIV protease inhibitor resistance (24). 
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Following in vitro stimulation with the IDV PR 76-84 peptide L VGPTPVNI, we 
observed specific lysis of HLA-A2 target cells pulsed with the IP-30 signal sequence 
peptide LLDVPTAA V in an individual with a high frequency of PBMC producing IFN-y 
in response to mv PR 76-84. Therefore, we tested 3 additional individuals with strong 
ex vivo PBMC IFN-y responses to mv PR 76-84 for CTL against IP-30 following in vitro 
stimulation with mv PR 76-84 (Fig. 3.1 a). Although there was no demonstrable ex vivo 
IFN-y release in response to the IP-30 signal sequence peptide in any case, even with 4-
fold higher levels of peptide than normally used (data not shown), in vitro stimulation of 
PBMC from a114 individuals with mv PR 76-84 activated CTL against target cells 
pulsed with the IP-30 signal sequence peptide (Fig. 3.1 b-e). None of 6 non-mY-infected 
HLA-A2 individuals generated CTL against the IP-30 signal sequence peptide following 
in vitro stimulation of their PBMC with mv PR 76-84, as shown for 4 of those 6 controls 
(Fig. 3.1 f-i). The mY-infected individuals tested had HLA-A2 as their only common 
HLA class I A orB molecule (039- A2,24; B18,73; 065- A2,3; B51,62; 078- A1,2; 
B18,41; 081-A2; B7,61), but to confirm that recognition of IP-30 signal sequence peptide 
was restricted by HLA-A2, we did cytotoxicity assays using partially matched BLCL 
target cells and C1R transfectants expressing either HLA-A2 or HLA-A3 as their only 
HLA class I molecule. Killing of target cells pulsed with the IP-30 signal sequence 
peptide was restricted to those target cells expressing HLA-A2 (Fig. 3.2). These data 
show that cross-reactive HLA-A2-restricted CTL against the IP-30 signal sequence 
peptide can be expanded in vitro by stimulating PBMC from mY-infected individuals, 
but not uninfected controls, with mv PR 76-84 peptide. 
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Figure 3.1. Frequency of IFN-y-producing CDS+ T cells in PBMC 
from IDV-infected HLA-A2 individuals in response to HIV and 
self-peptide. Frequency of CDS+ T cells in PBMC from 4 IllV -infected 
Ill-A-A2 individuals that produced IFN-y in response to stimulation 
with mv PR 76-84, IP-30 -11 to -3 or no peptide (a) and specific 
cytotoxicity ofT cells from those HIV -infected Ill-A-A2 individuals (b-
e) and 4 non-IITV-infected Ill-A-A2 controls (f-i) stimulated in vitro 
with mv PR 76-84 against autologous BLCL target cells pulsed with 
IllV PR 76-84 or IP-30 -11 to -3 peptides. 
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Figure 3.2. Specific cytotoxicity ofT cells from IDV -infected 
individuals stimulated in vitro with IDV PR 76-84. 
Specific cytotoxicity ofT cells from subjects 039 (a and c) and 081 (b) 
stimulated in vitro with HIV PR 76-84 against autologous (solid lines) 
HLA-A2-matched (dashed lines) and mismatched BLCL (dotted lines) 
pulsed with IP-30 -11 to -3 peptide. Panel c shows specific cytotoxicity 
against peptide-pulsed C1R transfectants expressing HLA-A2 (dashed 
lines) or A3 (dotted lines) only. 
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3.4.2. IFN -y does not indirectly activate IP-30-specific CTL 
To determine whether exposure to the HIV PR 76-84 peptide could activate IP-30-
specific CTL indirectly through IFN-y production and increased IP-30 expression, we 
incubated PBMC with high levels of IFN-y or with other peptides known to induce IFN-y 
release ex vivo from the PBMC of HIV-infected individuals expressing HLA-A2. 
Exposure of PBMC to the same in vitro conditions used to activate peptide-specific CTL 
with addition of 500 U/mL exogenous rhiFN-y did not induce IP-30 specific CTL (data 
not shown). To test whether localized endogenous IFN-y production activated IP-30-
specific CTL, we incubated PBMC from other HLA-A2 
individuals with additional HIV peptides known to trigger IFN-y production in the 
context of HLA-A2 or other co-expressed HLA molecules. Despite triggering ex vivo 
IFN-y production and activating strong in vitro CTL responses against themselves, none 
of the HLA-A2-restricted reverse transcriptase (RT) 33-41 peptide (AL VEICTEM), the 
HLA-B44-restricted HIV RT 203-212 peptide (EELRQHLLRW) or the HLA-B57-
restricted HIV Gag 147-155 peptide (LSPRTLNAW) activated CTL against IP-30 (Table 
3.1). These data indicate that up-regulation of IP-30 expression through IFN-y release 
does not account for in vitro activation of CTL against the IP-30 signal peptide with 
PBMC from HIV -infected individuals expressing HLA-A2. 
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Table 3.1. Activation of CTL by IFN-y-inducing HIV peptides other than PR 76-84 
Subject HLA HN peptide HLA SFC/106 Percent specific lysisb 
restriction PBMCa HN peptide IP-30 -11 to -3 
034 A2,3; B35,60 RT 33-41 A2 330 28/15/8 7/3/0 
043 A2,32; B14,62 RT 33-41 A2 65 60/44/43 5/0/3 
126 A2; B44,62 RT 203-212 B44 2710 50/39117 01010 
131 A2; B7,44 RT 203-212 B44 940 58/24/18 6/3/0 
071 A1,2; B18,57 Gag 147-155 B57 1175 40/23/6 111/0 
149 A1,2; B57,61 Gag 147-155 B57 325 36/20114 0/0/1 
aSpot forming cells were enumerated by IFN-y ELISPOT following incubation of PBMC with the 
indicated peptides. 
bCytotoxicity following in vitro stimulation of PBMC with the indicated HN peptide was 
measured against autologous BLCL pulsed with either the stimulating HN peptide or IP-30 -11 
to -3 signal peptide. Lysis values reported are at E:T ratios of 5:1, 2.5:1 and 1.25:1 with 
background lysis against unpulsed targets subtracted. 
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3.4.3. In vitro stimulation with the IP-30 self-peptide activates self-reactive and 
anti-IDV CTL 
Although it did not trigger ex vivo IFN-y release, we tested whether in vitro 
stimulation with the IP-30 signal peptide activated CTL against itself and/or the mv PR 
76-84 peptide previously shown to activate IP-30-specific CTL in vitro. We stimulated 
PBMC from the same donors who generated anti-IP-30 CTL in response to mv PR 76-
S4 in vitro with the IP-30 signal peptide. In all 4 cases, this activated both CTL against 
target cells pulsed with the IP-30 signal peptide and lllV -specific CTL against lllV PR 
76-S4 (Fig. 3.3 a-d). At the level of in vitro CTL activation, there was clear cross-
reactivity between mv PR 76-S4 and the IP-30 signal peptide and despite not inducing 
IFN-y release ex vivo, the IP-30 signal peptide was effective at in vitro stimulation of 
CTL against both itself and the PR 76-S4 peptide. Stimulation ofPBMC from non-IITV-
infected Ill-A-A2 controls with the IP-30 signal peptide did not activate CTL against IP-
30 in any case (Fig. 3.3 e-h), indicating that in vivo lllV infection primes CDS+ T cells for 
in vitro activation with the IP-30 signal peptide. 
3.4.4. Cross-reactivity between IDV PR 76-84 and IP-30 signal peptide-specific CTL 
Although the IP-30 signal peptide did not trigger ex vivo IFN-y production, once 
PBMC from subject OSl were stimulated in vitro with either the IP-30 signal peptide (Fig. 
3.4 a-d) or mv PR 76-S4 (Fig. 3.4 e-h), the cells did release IFN-y when exposed to 
BLCL pulsed with the IP-30 signal peptide (Fig. 3.4 band f). A similar fraction within 
each of the individual in vitro expanded CDS+ T cell populations produced IFN-y in 
response to either the IP-30 signal peptide or PR 76-S4 peptide (Fig. 3.4 b versus c 
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Figure 3.3. Specific cytotoxicity ofT cells from IDV -infected and 
uninfected individuals stimulated in vitro with IP-30. 
Specific cytotoxicity ofT cells from 4 HIV -infected HLA-A2 
individuals (a-d) and 4 non-HIV-infected HLA-A2 controls (e-h) 
stimulated in vitro with IP-30 -11 to -3 against autologous BLCL target 
cells pulsed with HIV PR 76-84 or IP-30 -11 to -3 peptides. 
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Figure 3.4. Intracellular IFN-y production by in vitro HIV PR 76-
84 or IP-30 peptide stimulated CDS+ T cells in response to IP-30 or 
HIV PR 76-84 peptides. Intracellular IFN-r production by CD8+ T 
cells stimulated in vitro for 14 days with IP-30 -11 to -3 signal peptide 
(a-d) or HIV PR 76-84 (e-h) and exposed for 5 hr to autologous BLCL 
pulsed with either no peptide (a and e), IP-30 -11 to -3 signal peptide (b 
and f), PR 76-84 (c and g) or pulsed with each peptide individually and 
combined as stimulators (d and h). The percentage of CD8+ T cells 
producing IFN-r is denoted in the upper right quadrant of each plot. 
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and f versus g) and there was no additive effect from combining sets of stimulators pulsed 
separately with one or the other peptide (Fig. 3.4 d and h). The same pattern was 
observed with CD8+ T cells from subject 039 (data not shown), suggesting a largely 
overlapping set of CD8+ T cells responds to the different peptides. 
To confirm that CTL against HIV PR 76-84 and the IP-30 signal peptide were 
actually cross-reactive and not reciprocally activated through some form of bystander 
mechanism, we did flow cytometry and depletion experiments with peptide-loaded Ill.A-
A2:Ig dimer and carried out cold target inhibition assays. Flow cytometry with the HLA-
A2:Ig dimer loaded with HIV PR 76-84 revealed a similar sized population 
of dimer-positive cells (-25%) following stimulation of PBMC from subject 065 with 
either HIV PR 76-84 (Fig. 3.5 a) or the IP-30 signal peptide (Fig. 3.5 b). The HLA-A2:Ig 
dimer loaded with IP-30 signal peptide failed to stain T cells within either the HIV PR 76-
84 or IP-30 signal peptide in vitro stimulated CTL populations. Similar results were 
obtained with subjects 039 and 081 (data not shown). When PBMC from non-HIV-
infected HLA-A2 individual MG were stimulated in vitro with either HIV PR 76-84 (Fig. 
3.5 c) or the IP-30 signal peptide (Fig. 3.5 d), flow cytometry with the HLA-A2:Ig dimer 
loaded with HIV PR 76-84 revealed no dimer positive cells relative to the empty dimer 
control. Identical results were obtained with stimulated PBMC from non-HIV -infected 
HLA-A2 individual SO (data not shown). 
Since the HLA-A2:Ig dimer loaded with HIV PR 76-84 stained T cells within both 
HIV PR 76-84 and IP-30 signal peptide stimulated CTL populations, we used this dimer 
for depletion experiments. Depletion of effector cells from subject 081 with the HIV 
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Figure 3.5. Immunofluorescent labeling of T cells from IDV-
infected and uninfected individuals following in vitro stimulation 
with HIV PR 76-84 or IP-30 peptides. Immunofluorescent labeling of 
T cells from HIV -infected subject 065 (a and b) and non HIV -infected 
lll..A-A2 control MG (c and d) following in vitro stimulation with HIV 
PR 76-84 (a and c) or IP-30 -11 to -3 (band d) with lll...A-A2:Ig dimer 
loaded with either HIV PR 76-84 (unshaded histogram) or no peptide 
(shaded histogram). 
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PR 76-84loaded lll...A-A2:Ig dimer and goat-anti-mouse lgG coupled magnetic beads 
reduced killing of lll...A-A2 target cells pulsed with the IP-30 signal peptide to 
background levels. It also substantially reduced killing of lll...A-A2 target cells pulsed 
with HIV PR 76-84, whether the effector cells were generated by stimulation with IDV 
PR 76-84 (Fig. 3.6a) or the IP-30 signal peptide -11 to -3 (Fig. 3.6 b). Depletion of 
effector cells from subjects 039, 065 and 078 produced equivalent results (data not 
shown). 
When CTL were raised in vitro by stimulation with either the IP-30 signal peptide 
or HIV PR 76-84, killing of lll...A-A2 target cells pulsed with IP-30 signal peptide or HIV 
PR 76-84 was effectively inhibited by cold target cells pulsed with HIV PR 76-84 (Fig. 
3.6c). Cold target cells pulsed with the IP-30 signal peptide inhibited killing of lll...A-A2 
target cells pulsed with the IP-30 signal peptide, but had little effect on killing of lll...A-
A2 target cells pulsed with HIV PR 76-84 (Fig. 3.6d). Similar results were observed with 
CTL from subjects 078 and 081 (data not shown). Thus, both functional and phenotypic 
assays demonstrate cross-reactivity between the IP-30 signal peptide and HIV PR 76-84 
and indicate that with PBMC from lll...A-A2 HIV -infected individuals, the IP-30 signal 
peptide can effectively activate CTL against HIV PR 76-84 in vitro. 
3.4.5. The CTL interaction with HLA-A2/IP-30 self-peptide is lower avidity than 
with HLA-A2/HIV PR 76-84 
Escape of IP-30-specific CTL from thymic deletion, inability to stimulate ex vivo 
IFN-y release, inefficient inhibition of killing with IP-30 signal peptide-pulsed cold 
targets and failure of the lll...A-A2:Ig!IP-30 peptide dimer to stain IP-30-specific CTL 
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Figure 3.6. Specific cytotoxicity of effector cells following depletion 
with HIV PR 76-84-leaded HLA-A2:Ig dimer or cold target 
inhibition. Effect of depleting cells binding the HLA-A2:Ig dimer 
loaded with IllV PR 76-84 on specific cytotoxicity of effector cells from 
subject 081 stimulated in vitro with IllV PR 76-84 (a) or IP-30 -3 to -11 
(b) against autologous BLCL target cells pulsed with IllV PR 76-84 or 
IP-30 -3 to -11 and cold-target inhibition of cell-mediated cytotoxicity 
against BLCL pulsed with either the IP-30 -11 to -3 signal peptide or 
IllV PR 76-84. HLA-A2 expressing BLCL cold targets were pulsed 
with no peptide (c and d, solid lines) IllV-PR 76-84 (c, dashed lines) or 
IP-30 -11 to -3 (d, dashed lines). Cold targets were used at a 5:1 cold to 
hot target ratio to inhibit killing by IllV PR 76-84 stimulated CTL at the 
E:T ratios shown. 
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suggest that the T cell receptor interaction with the Ill..A-A2/IP-30 signal peptide 
complex is of relatively low avidity (25, 26). We compared the avidity of CTL from 
subjects 065 and 078 generated by in vitro stimulation with either HIV PR 76-84 or the 
IP-30 signal peptide for Ill...A-A2 target cells pulsed with the corresponding peptides by 
titrating peptide concentrations in cytotoxicity assays. Regardless of whether the CTL 
were generated by in vitro stimulation with HIV PR 76-84 (Fig. 3.7 a and c) or the IP-30 
signal peptide (Fig. 3.7 band d), killing of target cells pulsed with HIV-PR 76-84 fell to 
50% of baseline killing at< 0.2 nM HIV-PR 76-84, an approximately 1000-fold lower 
peptide concentration than did killing of target cells pulsed with the IP-30 signal peptide. 
While a lower affinity of Ill...A-A2 binding for the IP-30 peptide than HIV PR 76-84 
could also explain these results, this is unlikely for several reasons. Firstly, IP-30 was 
identified as a very prominent self-peptide in the context of Ill...A-A2 molecules purified 
from lymphoid cells (18). Secondly, the IP-30 signal peptide sequence fits the motif for 
Ill...A-A2 binding and ranks higher than HIV PR 76-84 using the 2 most common 
algorithms for predicting Ill...A binding affinity. With 
http://bimas.dcrt.nih.gov/molbio/hla bind site, IP-30 -11 to-3 scores 47.3 and lllV PR 76-
84 scores 1.6. Using the Rammensee lab developed site http://www.syfpeithi.de, the IP-
30 -11 to-3 and HIV PR 76-84 peptides score 28 and 18 respectively. 
3.5. Discussion 
The potential for molecular mimicry to activate cross-reactive T cells during viral 
infections relates to the extent of peptide mimicry, from the perspective of host Ill...A 
molecules and T cell receptors, and to the degree of self-tolerance imposed upon T cells 
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Figure 3. 7. Peptide titration curve for cytotoxicity of effector cells 
activated by in vitro stimulation with IDV PR 76-84 or IP-30 peptides. 
Peptide titration curves for cytotoxicity of effector cells from subject 078 
(a and b) and 065 (c and d) activated by in vitro stimulation with IllV PR 
76-84 (a and c) or IP-30 -11 to -3 (band d) at an E:T ratio of 5:1 against 
autologous BLCL targets pulsed with decreasing concentrations of either 
IllV PR 76-84 or IP-30 -11 to -3 as indicated by the legend. Dashed 
vertical lines to the X axis indicate the peptide concentrations at which 
killing of peptide targets fell to 50% of maximum values. 
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reactive with the analogous self peptides. Self-reactive T cells that avoid thymic and 
peripheral deletion may persist in the periphery in an effectively tolerant state invoked by 
their inactivation, suppression or ignorance. While this is normally a stable situation, 
perturbations accompanying viral infections, including the introduction of more 
immunogenic variants of self peptides, may challenge the tolerance imposed on self-
reactive T cells. In this study, we found that following illV infection, CDS+ T cells 
reactive against a self peptide derived from IP-30 could be readily activated and expanded 
in vitro by exposure to either the foreign illV PR 76-S4 peptide or to the self IP-30 -11 to 
-3 signal peptide. Despite acquiring the capacity to expand and differentiate into CTL in 
vitro in response to self peptide, the CDS+ T cells cross-reactive with illV PR 76-S4 
didn't release IFN-y ex vivo when exposed to the self peptide. This presumably reflects 
the relatively low avidity of the TCRIHLA-A2/IP-30 signal peptide interaction that 
allowed the IP-30-specific T cells to originally escape thymic deletion and persist in the 
periphery without effecting symptomatic autoimmunity (25,26). Low avidity relative to 
the illV PR 76-S4 peptide recognition was reflected in an approximately 1000-fold lower 
concentration of mv PR 76-S4 than IP-30 -11 to -3 required to trigger 50% maximal 
lysis of peptide-pulsed targets, inefficient inhibition of cytotoxicity against targets pulsed 
with mv PR 76-S4 by cold targets pulsed with IP-30 -11 to -3 and failure of the HLA-
A2:Ig dimer loaded with IP-30 -11 to -3 to stably bind the cross-reactive CDS+ T cells. 
The higher avidity interaction with mv PR 76-S4 expands cross-reactive CDS+ T 
cells specific for the IP-30 signal peptide in vivo, and in so doing, increases their 
sensitivity to activation and expansion by the IP-30 signal peptide itself, at least in vitro . 
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This situation, effected by viral infection, parallels a proposed approach to therapeutic 
vaccination for cancer where synthetic peptide variants are used to activate T cells against 
self-peptides expressed on tumor cells, when the self-peptides themselves do not activate 
the T cells (27). In these cases, self-reactive T cells react with higher avidity against 
synthetic heteroclitic variant peptides and once activated and expanded by exposure to the 
variants, selectively attack tumor cells, which express higher levels of the analogous self 
peptide than do normal host cells (27). In this study, we identified a viral peptide that 
acts as the synthetic heteroclitic variant activating self-reactive T cells against a self-
peptide expressed at higher levels in lymphoid cells exposed to IFN-y. Activation, by 
HIV PR 76-84, of cross-reactive CTL against an IFN-y-inducible protein widely 
expressed in lymphoid cells could have dangerous implications for autoimmunity, 
especially when elevated IFN-y levels during periods of viral replication upregulate IP-30 
expression (17). As in the selective targeting of tumor cells by autoreactive CTL, 
activation and proliferation of IP-30-specific CTL against a backdrop of elevated IFN-y 
levels could selectively target IFN-y exposed APC expressing elevated levels of IP-30 
and thereby contribute to the APC dysfunction and lymphoid architectural destruction 
characteristic of progressive HIV infection. However, there is as yet no evidence of any 
relationship between HIV disease progression and CTL against HIV PR 76-84. Of 46 
HLA-A2 HIV -infected individuals we tested by IFN-y ELISPOT, 17 had T cells reactive 
with HIV PR 76-84 and 7 of these 17 generated HIV PR 76-84 and IP-30 -11 to -3 cross-
reactive CTL following in vitro peptide specific stimulation. While it is clearly a subset 
of HLA-A2 HIV -infected individuals that possess these CTL, there was no clear 
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indication that this subset had a clinically distinct pattern of disease progression and 
longitudinal studies will be needed to address this issue. 
Current models ofT cell selection hold that ens+ thymocytes are positively 
selected through interaction with self-peptides ubiquitously expressed with the MHC 
class I molecules of cortical epithelial cells. Subsequent negative selection eliminates 
only those ens+ T cells that react with high avidity against endogenous peptide/MHC 
class I molecule complexes expressed on bone marrow-derived APC at the cortico-
medullary junction or in the medulla (25). Therefore, selection of ens+ T cells with the 
capacity for high avidity interactions with foreign peptide/MHC class I complexes is 
absolutely dependent upon those ens+ T cells engendering low avidity self-reactivity. 
Within the normal environmental milieu, such low avidity self-reactive T cells are non-
pathogenic, however, increased expression of the self-peptide, alterations in the 
environment or activation, proliferation and differentiation of self-reactive CTL in 
response to foreign peptides could shift the situation towards symptomatic autoimmunity. 
The ability of the IP-30 signal peptide itself to activate and expand CTL in vitro, once 
they have been activated in vivo by HIV PR 76-S4, suggests that the in vivo activation and 
or expansion of cross-reactive CTL lowers the threshold for breaking the effective 
tolerance of these T cells for self tissue. While the potential negative consequence of 
CTL against uninfected lymphoid cells is obvious, as long as the relatively low avidity of 
CTL against IP-30 protects against symptomatic autoimmunity, there could be substantial 
advantages to cross-reactivity between anti-viral CTL and a prominent self peptide up-
regulated by pro-immune cytokines such as IFN-y. One previously identified positive 
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consequence of activation of low avidity self-reactive T cells can be selective targeting of 
tumor cells. In the case of the self-peptide we identified as functionally analogous to an 
IllV CTL epitope, its broad distribution in lymphoid cells, prominent basal representation 
in HLA-A2 molecules and up-regulation in response to IFN-y could all potentially benefit 
the anti-IDV CTL response. Based on the premise that cross-reactive self-peptides are 
required for homeostatic maintenance of anti-IDV memory T cells when mv replication 
is undetectable, the broad distribution and prominent representation of IP-30 -11 to -3 
may convey an advantage on anti-IDV CTL manifesting lower avidity recognition of that 
particular self peptide. In this context, we observed a persistent high frequency of CDS+ 
T cells against IllV PR 76-84 in one individual (subject 081), despite antiretroviral 
suppression of IllV replication to undetectable levels for over 6 years. When IllV 
replication or any other event that elevates IFN-y levels occurs, the selective up-
regulation of IP-30 might favor propagation of those anti-viral T cells with the capacity 
for functional recognition of IP-30 -11 to -3. The differential avidity would ensure an 
impact only on those cross-reactive memory T cells previously activated by higher avidity 
interactions with foreign peptides and possibly allow a self peptide to selectively activate 
anti-viral CTL. Thus, both in terms of their homeostatic maintenance and the potency of 
their response to secondary challenge, CTL reactive with self peptides such as IP-30 -11 
to -3 may have a significant advantage. 
Although we identified CTL against IP-30 -11 to -3 specifically through their 
cross-reactivity with IllV PR 76-84, it is quite feasible that a variety of CTL restricted to 
HLA-A2 would have lower avidity interactions with IP-30 -11 to -3. Minimal sequence 
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homology between IP-30 -11 to -3 and HIV PR 76-S4 as well as between other reported 
cross-reactive eTL epitopes such as the influenza A matrix protein peptide MI 5S-66 
(GILGFVFTL) and HIV p17 77-S5 (SL YNTVATL) illustrate the surprising level of 
promiscuity of ens+ T cell recognition of peptides with a common restricting element 
(2S). Previous studies showed that a broad T cell receptor repertoire is selected even 
when thymic presentation is restricted to a single MHe/peptide combination (29). The 
surrogate function of self-peptides in positive selection ofT cells with high avidity for 
foreign peptides may be recapitulated in the periphery following initial activation of these 
T cells during infection if the expression pattern of the surrogate self peptide is 
appropriate. Depending upon the relative stringency of requirements for expression 
levels and avidity threshold to serve as a positively selecting surrogate peptide in the 
periphery versus during thymic selection, the autoreactivity that drives positive selection 
of the T cell repertoire may also play a major role in evolution of the T cell response 
against foreign agents. 
In summary, this study demonstrates cross-reactivity between HIV PR 76-S4 and 
IP-30 -11 to -3 at the level of ens+ T cell recognition. The interaction with IP-30 is 
lower avidity and the ens+ T cells require in vivo priming with HIV PR 76-S4 in order to 
respond to IP-30 -11 to -3 in vitro. Although such cross-reactivity raises the possibility of 
autoreactivity against APe, in the context of our current understanding ofT cell selection, 
the IP-30 -11 to -3 signal peptide appears to be an ideal surrogate peptide for selection, 
maintenance and expansion of ens+ T cells against foreign agents. 
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4. Thesis Summary 
4.1. Summary 
This was a proof-of-concept study to determine whether mutations conferring 
resistance to commonly prescribed antiretroviral drugs could sustain or enhance immune 
recognition of HIV. As described in chapter two, we tested wild-type and variant HIV 
CTL epitopes incorporating drug resistance mutations and identified several mutations 
which were able to sustain CTL recognition in HIV -infected donors. The variant-specific 
responses we detected represent novel HIV CTL epitopes which are recognized in the 
context of common alleles Ill..A-A2, -A3, -B35 and -B44. We detected CTL responses to 
epitopes containing single as well as dual amino acid substitutions conferring resistance 
to antiretroviral drugs. A significant fraction of donors responded to these variant CTL 
epitopes and, in most cases, recognition of specific drug resistance mutations was 
associated with exposure to the appropriate drug that selected the mutation. In some 
instances, CTL epitopes containing drug resistance mutations were more immunogenic 
than corresponding wild-type consensus epitopes. Thus, we demonstrated that HIV drug 
resistant variants which emerge under the selective pressure of antiretroviral therapy can 
sustain and, in some cases, enhance recognition by CTL. 
Demonstrating immunogenicity of drug resistant HIV may have important 
implications for improving the long-term efficacy of antiretroviral therapy. Treatment of 
HIV-infected individuals often involves sequential and alternating combinations of NRTI, 
NNRTI and PI, which can result in high level resistance to drugs within all three classes 
of inhibitors. Resistance to novel anti-HIV compounds has also been documented. The 
fusion inhibitor Enfuvirtide which was recently introduced into clinical practice and the 
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integrase inhibitor S-1360 presently in clinical trials have both been shown to select for 
resistance mutations (1, 2). Identification of drug resistance mutations that can sustain or 
enhance CTL recognition provides evidence in support of developing treatment and 
vaccine strategies which combine immune and drug selection pressures to prevent 
emergence and transmission of drug resistant illV. Ultimately, this could delay or even 
prevent the outgrowth of drug resistant variants, which is the primary cause of treatment 
failure in HIV -infected individuals. 
We also detected strong CTL responses against an illV-unrelated control peptide 
in several illV -infected donors. This peptide was derived from lP-30, a self protein 
involved in antigen processing and presentation (3). Since lP-30 peptide-specific CTL 
were only detected in illV-infected donors, we investigated the basis for activation of 
these self-reactive CTL. Chapter 3 outlines our results showing that functional cross-
reactivity between an illV protease peptide and the lP-30 self-peptide led to the 
activation of these self-reactive CTL. Cross-reactivity between an illV peptide and a 
prominent self-peptide indicates the potential for illV -specific CTL to contribute to 
prominent immunopathology in illV infection. However, although lP-30-specific CTL 
were generated at high frequencies in illV -infected donors, they did not produce any 
apparent immunopathology. Conversely, cross-reactivity of illV peptide-specific CTL 
for a self-peptide may allow for continuous antigenic stimulation to maintain anti-HIV 
memory CTL when illV replication is suppressed by ART. 
The results presented in the second chapter might be important for the 
development of novel anti-illV treatment and vaccine strategies which combine immune 
and drug selection pressures. For individuals on ART, emergence and accumulation of 
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drug resistance mutations is a significant obstacle to long-term suppression of mv 
replication. As well, since CD4+ T cell help is critical for maintaining the effectiveness 
of IllY-specific CTL (4), progressive loss of CD4+ T cells may impair generation of CTL 
responses against novel epitopes generated by viral mutations as disease progresses. 
Early treatment with drugs that select for resistance mutations that sustain or enhance 
recognition by IllV -specific CTL may allow targeting of drug resistant IllV before loss 
of CD4+ T cells can impair CTL function. Furthermore, wild-type and corresponding 
variant epitopes incorporating drug resistance mutations that sustain or enhance 
recognition by CTL may be incorporated into a IDV vaccine to generate pre-existing 
immunity against wild-type and drug resistant IDV. In the event of failure to protect 
against mv infection, subsequent treatment with drugs that select for resistance 
mutations susceptible to CTL may allow for long-term immune control of mv, especially 
if those CTL are pre-activated by immunization. 
While we have laid the basis for recognition of CTL epitopes incorporating drug 
resistance mutations which suggests potential efficacy of convergent immune and drug-
based treatment and vaccine strategies, several important questions remain. First, is there 
a correlation between CTL recognition of drug resistant mv and improved immune 
containment of mv in treated individuals? Due to the limited number of epitopes 
examined and small sample size of our cohort, we were unable to provide statistically 
significant evidence for this. However, broad mv -specific CTL responses which cross-
react with potential escape mutations are thought to contribute to prolonged immune 
control in the absence of antiretroviral therapy (5). Therefore, we anticipate improved 
control of mv replication in treated individuals who exhibit CTL recognition of epitopes 
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incorporating drug resistance mutations. Furthermore, there may also be selection against 
drug resistance mutations when they are more immunogenic than corresponding wild-
type epitopes, thus rendering HIV more susceptible to antiretroviral drugs. 
Second, is there evidence for viral mutations that simultaneously escape both 
immune and drug selection pressures? HIV has an extraordinary capacity to mutate and 
prolonged viral exposure to both immune and drug selection pressures may result in 
further mutations providing complete escape from both. The functional importance of 
HIV pol gene products, as well as selection and maintenance of drug resistance mutations 
which impair viral fitness implies that there are strict limitations on sequence diversity of 
the pol gene. This suggests that combining immune and drug selection pressures may 
provide sufficient constraints to prevent or delay escape from dual immune and drug 
selection pressures. 
Third, we focused our study on epitopes incorporating drug resistance mutations 
which were able to sustain or enhance CTL recognition. Mutations within CTL epitopes 
can also generate altered peptide ligands which may lead to TCR antagonism of CTL (6). 
Altered peptide ligands can bind to and drive the proliferation of wild-type specific CTL 
which may fail to kill target cells presenting the altered peptide, resulting in failure to 
elicit variant peptide-specific CTL (7). Altered peptide ligands may also serve as decoy 
peptides which retain the ability to interact with wild-type specific CTL and prevent 
targeting of corresponding wild-type epitope sequences (8, 9). Further studies on the 
interaction of CTL epitopes incorporating drug resistance mutations with wild-type-
specific CTL should establish whether these mutations can generate altered peptide 
ligands that antagonize the CTL response to either wild-type or drug resistant HIV. 
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Lastly, the results of this study were based on CTL responses in a cohort of mv -1 
clade B infected individuals. Most mv infections that account for the global epidemic 
are comprised of non-clade B infections which occur primarily in Africa and Asia. 
Compared with donors in our cohort, populations within these regions are exposed to 
different IllV -1 clade isolates and show some differences in HLA allele frequencies. 
Therefore, it will be important to test CTL recognition of drug resistant variants in 
different ethnic populations in the context of HLA alleles and mv -1 clade isolates that 
predominate in these populations. 
4.2. Future directions 
The most prevalent IITV-1 clade circulating in North America and Europe (clade 
B) represents just one of multiple clades circulating worldwide. Within subgroup M, the 
major group oflllV-1, eleven distinct clades (Al, A2, B, C, D, F1, F2, G, H, J and K) 
occur with varied frequency in different geographic regions. Recent estimates indicate 
that less than 15% of worldwide infections are due to mv clade B, while nearly 75% of 
new mv infections are due to subtypes A and C (10). Circulating recombinant forms 
(CRF) of mv generated by recombination of distinct subtypes as well as viral 
quasispecies generated following emergence and accumulation of viral mutations within 
IITV-infected individuals also contribute to the global diversity of mv. This enormous 
variability of mv poses a significant challenge for the development of a globally 
effective HIV vaccine or any broad-based application of vaccines targeting drug 
resistance mutations. 
Broad cross-reactivity of mv -specific CTL epitopes has been observed in clade B 
and non-clade B infected individuals (11, 12) and may account for the improved clinical 
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outcome of some Ill..A-B57+ long term nonprogressors (LTNP) (5). However, cross-
clade recognition of mv -specific CTL epitopes incorporating drug resistance mutations 
has not yet been studied. Comparison of commonly circulating clades shows that some 
CTL epitopes share complete sequence homology, while for others there is only partial 
sequence homology. We have already demonstrated that IDV-1 clade B CTL epitopes 
incorporating drug resistance mutations sustain antigenicity in mv -infected individuals. 
Since several mutations conferring resistance to antiretroviral drugs are conserved across 
multiple clades (13), we sought to determine whether CTL activated in IDV-1 clade B 
infected individuals cross-react with corresponding clade A and C wild-type and variant 
peptides incorporating drug resistance mutations. 
Based upon the epitopes to which we observed strong CTL responses in our 
cohort of mv -1 clade B infected individuals, we tested recognition of corresponding 
epitopes from clades A and C, two of the most prevalent IDV-1 clades circulating in 
Africa (R. Mason, unpublished data). Comparison of the consensus clade B CTL 
epitopes PR 76-84, RT 33-41, RT 107-115, RT 179-187 and RT 203-212 CTL with 
consensus clade A and C sequences showed complete sequence homology across all three 
clades for PR 76-84 and RT 107-115. However, only partial homology across clades A, 
Band C was observed for RT 33-41, RT 179-187 and RT 203-212 which are restricted by 
Ill..A-A2/-A3, -A2 and -B44, respectively. Since these Ill..A types also occur in the 
majority of individuals where mv clades A, Band C predominate, these epitopes were 
chosen for analysis of cross-clade recognition of mv -1 CTL epitopes incorporating drug 
resistance mutations. 
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A significant fraction of donors had IllV -1 clade B-specific CTL that cross-
reacted with corresponding clade A and C wild-type and variant peptides. For the Ill..-A-
A2/A3-restricted RT 33-41 epitope, several donors with clade B RT 33-41-specific CTL 
also recognized at least one clade A or C wild-type or M41L variant peptide. Among 
Ill..-A-A2+ donors RT 33-41 clade B peptide-specific CTL were primarily cross-reactive 
for clade A derived RT 33-41 wild-type and M41L variant peptides with limited cross-
reactivity for clade C derived wild-type and M41L variant peptides. In the context of 
Ill..-A-A3, CTL were fully cross-reactive for clade A and C wild-type and M41L variant 
peptides. Thus, for the RT 33-41 sequence, Ill..-A-A3-restricted CTL displayed broader 
cross-clade reactivity for corresponding wild-type and variant peptides from clades A and 
C compared with Ill..-A-A2-restricted CTL. 
Although cross-clade recognition of RT 179-187 was detected in only one donor, 
we later observed that this epitope, which has been documented to be an Ill..-A-A2-
restricted epitope, was also recognized by several Ill..-A-A3+ donors. Therefore, further 
testing of clade A and C wild-type and variant RT 179-187 peptides may reveal broader 
cross-clade reactivity in the context of Ill..-A-A3. 
Finally, a number of donors with clade B RT 203-212 wild-type or variant-
specific CTL also recognized corresponding wild-type clade A or C derived peptides. For 
some donors, the corresponding clade C-derived wild-type peptide was more 
immunogenic than the homologous clade B epitope. Surprisingly, we also observed 
Ill..-A-B44+ donors who responded to this wild-type clade C epitope although they did not 
recognize either the wild-type or variant epitope sequence from clade B. 
96 
Viral genotyping confirmed clade B infection for all donors in our cohort. Thus, 
our preliminary results indicate that cross-clade CTL recognition of wild-type and variant 
peptides incorporating drug resistance mutations can occur even in the absence of 
exposure to multiple IllV clade variants. Furthermore, the observation that RT 33-41 and 
RT 179-187 were able to elicit strong CTL responses in the context of both HLA-A2 and 
-A3 renders them ideal targets for treatment and vaccine strategies aimed at eliciting 
IllV -specific CTL since both alleles are common within different ethnic populations. 
Finally, it will also be important to test additional IITV-specific CTL epitopes overlapping 
common drug resistance mutations restricted by HLA alleles that occur common! y in 
regions where non-clade B IllV isolates predominate. 
With over ten major IllV -1 clades distributed at varying frequencies in different 
geographic regions, protection against multiple clades will be essential for any broadly 
applicable IllV treatment or vaccine strategy. The increasing prevalence of CRFs of 
IllV -1 as well as documented cases of co-infection and superinfection with distinct clades 
demonstrates that exposure to multiple clades is not uncommon (14-17). An effective 
immune response directed against one IllV -1 clade or variant does not necessarily protect 
against subsequent infection with a different clade or even a closely related strain (18). 
Epitopes which elicit broad cross-clade CTL responses are more likely to afford 
protection against multiple clades. 
Our preliminary findings demonstrate the occurrence of cross-clade CTL 
recognition of IllV epitopes overlapping sites of drug resistance mutations which can be 
used to address the problem oflllV-1 clade diversity. Anti-IITV-specific CTL directed 
against multiple conserved epitopes have been documented in LTNP and may contribute 
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to their slow disease progression (5). Thus, it may be possible to provide antiretroviral 
therapy for IllY-infected individuals which selects for drug resistance mutations that 
sustain CTL recognition of wild-type and variant epitopes from multiple clades, in order 
to protect against heterologous mv -1 clades and prolong the effectiveness of 
antiretroviral treatment. CTL epitopes incorporating drug resistance mutations that elicit 
broad cross-clade reactivity for wild-type and drug resistant variants from multiple clades 
are also ideal for inclusion in CTL-inducing vaccines to prevent selection and 
transmission of heterologous mv -1 clade isolates. 
4.3. Conclusions 
We identified six common antiretroviral drug resistance mutations that sustained 
and in some cases, enhanced the antigenicity and immunogenicity of mv -1 pol CTL 
epitopes. Variable patterns of cross-reactive and selective recognition of wild-type and 
corresponding variant epitopes indicated a relatively diverse population of CDS+ T cells 
reactive against these epitopes. The frequency and diversity of CTL reactivity against the 
variant peptides incorporating drug resistance mutations and their ability to activate and 
expand CTL precursors in vitro illustrates a significant functional interface between the 
immune system and antiretroviral therapy. Thus, drug resistant variants of mv are 
susceptible to immune selective pressure which could be applied to combat transmission 
or emergence of antiretroviral drug resistance and to enhance the immune response 
against mv. 
Stimulation of PBMC from HLA-A2 IllV -1-infected individuals with the HLA-
A2-restricted mv PR peptide 76-84 activated CTL against the IP-30 signal self-peptide. 
The IP-30 signal peptide also activated CTL in vitro against itself and mv PR 76-84 
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suggesting T cell cross-reactivity between the two peptides. As well, the T cell 
interaction with HIV PR 76-84 was higher avidity than with the IP-30 signal peptide, 
indicating that HIV PR76-84 is a heteroclitic peptide variant of the IP-30 signal peptide, 
which has implications for immune memory and autoimmunity. 
4.4 Significance of Research 
HIV treatment and vaccine strategies that combine immune and drug selection 
pressures could become increasingly important as the epidemic progresses due to the 
rapid evolution of HIV. Transmission and replication of HIV within the population has 
resulted in selection pressure on the virus to escape Ill...A-mediated immune responses 
(19, 20). The most frequent Ill...A alleles within infected populations are more likely to 
have influenced viral adaptation through mutations in CTL epitopes restricted by 
common Ill...A alleles. Therefore, it may be beneficial to use antiretroviral drugs to select 
for mutations that enhance CTL recognition in individuals with common Ill...A alleles. 
Further analysis of the effect of drug resistance mutations on CTL recognition throughout 
the entire pol gene may reveal novel epitopes incorporating drug resistance mutations 
which lie outside of previously defined consensus epitopes. 
Since the first reported case of HIV over twenty year ago, more than 20 million 
people have died from HIV/AIDS. The Joint United Nations Programme on HIV/AIDS 
estimated over 3 million AIDS related deaths and nearly 5 million new HIV infections in 
2004, indicating that the best hope for bringing an end to this epidemic is a vaccine that 
can provide sterilizing immunity against HIV. Unfortunately, there are numerous 
obstacles facing the development of an HIV vaccine. To date, only two candidate HIV 
vaccines have advanced through phase ill clinical trials in humans and both ultimately 
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failed to demonstrate protection against HIV (21, 22). In addition to safety and efficacy, 
other issues such as affordability, ease of administration and distribution to populations 
most severely affected by HIV/AIDS will likely take many years to resolve. In the 
meantime, there is an urgent need to treat the nearly 40 million people currently infected 
with HIV and the many more who are likely to become infected before a successful 
prophylactic vaccine becomes available. Our results may contribute to the development 
of novel HIV treatment and vaccine strategies that may facilitate more effective 
management of HIV infection and, therefore, towards the long-term survival of HIV-
infected individuals. 
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